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CHAPTER ONE 
 
INTRODUCTION 
 
Over 1.4 million Americans have been diagnosed with Inflammatory Bowel Disease 
(IBD), and ulcerative colitis (UC) makes up approximately half of those diagnoses. IBD remains 
a prominent medical issue not only because of the sheer number of Americans presenting with 
the disease each year, but also because the exact mechanisms behind disease flare onset remain 
elusive1-3.  Unlike some other chronic diseases, UC cycles between periods of remission and 
flare. Periods of disease remission can unexpectedly and seemingly without cause turn into 
periods of active disease – an UC flare1-5, which is characterized by intense abdominal pain, 
increased weight loss, intestinal inflammation, rectal bleeding, and dehydration.  Reappearance 
of UC symptoms during a flare stem from increases in intestinal inflammatory cytokines of IFN-
γ, IL-1, IL-6, and TNF-α, which can lead to a dysbiosis of the colonic microbiome perpetuating 
the UC flare period6-11.  No cure exists for UC.  So, patients must obtain symptomatic relief 
through the use of drug and/or surgical therapies12-14.  Management of UC requires patients to 
avoid stress, certain foods, and alcohol, as all three can potentially induce flare periods of UC15. 
Interestingly, a widespread recommendation to IBD patients for avoidance of a flare 
period is ‘Don’t Drink Alcohol’ as some recent work has correlated alcohol consumption with 
increased GI symptoms in patients with IBD.  Alcohol alone not only induces a systemic pro-
inflammatory response, but can also be directly harmful to gut barrier integrity. However, how 
alcohol could result in the exacerbation of UC in murine models of colitis has yet to be 
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elucidated.  Understanding how alcohol consumption exacerbates UC flare will allow for 
therapeutic intervention to not only prevent UC flare, but also improve the quality of life in 
patients suffering from UC. 
On the other hand, UC remission is associated with periods of asymptomatic disease, 
which relies on elevated levels of IL-22 to mediate intestinal tissue repair mechanisms.  IL-22, a 
member of the IL-10 family, is a unique cytokine in that it is produced by a number of different 
immune cells.  Its receptor is only found on cells of non-hematopoietic origin, such as epithelial 
cells. Once bound to its receptor, IL-22 has been shown to signal through several different 
downstream molecules, however, the signal transducer and activator of transcription factor-3 
(STAT3) is the best described. IL-22 has many functions when present in the intestine, which 
include promoting mucus secretion, enhancing epithelial stem cell proliferation, and increasing 
anti-microbial peptide secretion from intestine epithelial cells (IECs).   
This led us to our central hypothesis that alcohol consumption alters IL-22 release and 
subsequently impairs defense mechanisms following DSS-induced colitis, thus perpetuating UC 
flare.  To test our central hypothesis, we first generated a murine model of binge alcohol 
consumption following a DSS-induced colitis flare.  To address current gaps in the field of 
alcohol and colitis we designed three specific aims.  Aim 1 examines whether binge alcohol 
consumption exacerbates UC flare and characterizes immune cell IL-22 responses to binge 
alcohol after DSS-induced colitis. Aim 2 evaluates whether gut barrier breakdown in DSS-colitis 
is further impaired with alcohol exposure.   Finally, Aim 3 elucidates whether IL-22 normalizes 
gut barrier integrity after DSS-colitis and binge alcohol exposure.  
To examine how alcohol could exacerbate an UC flare, we utilized a 2% dextran sodium 
sulfate (DSS) solution in the drinking water of mice followed by a 3-day binge alcohol paradigm.  
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Increased weight loss, colonic shortening, histopathology by hematoxylin and eosin (H&E) 
staining, and large intestine inflammation by ELISA.  Large intestine lamina propria (LP) cells 
were isolated and analyzed for immune cell IL-22 production. We administered recombinant 
mouse IL-22 via intraperitoneal (i.p.) injection or the probiotic, Lactobacillus delbrueckii, to 
assess the role of IL-22 and its signaling through STAT3 in mediating protection against 
perpetuation of UC flare by binge alcohol.   Inoculation with Citrobacter rodentium following 
colitis and alcohol was used to elucidate enhanced susceptibility to infection.       
Together, these studies give insight into how the intestinal barrier is damaged on a 
molecular level following alcohol and colitis, and the mechanism by which IL-22 is protective to 
the intestine following the combined insult. Our findings present a potential new option for UC 
patient therapy and may also translate to others with conditions that damage the intestinal barrier. 
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CHAPTER TWO  
 
REVIEW OF RELATED LITERATURE: EFFECTS OF ALCOHOL AND ULCERATIVE 
COLITIS ON THE INTESTINAL IMMUNE BARRIER AND MICROBIOME 
 
Inflammatory Bowel Disease 
Inflammatory Bowel Disease (IBD) consists of two main chronic disorders: Crohn’s 
Disease (CD) and Ulcerative Colitis (UC).  Incidence and prevalence of both CD and UC have 
steadily risen in nations such as North America and Europe since they were first described in 
1932 and 1859, respectively.  However, the adoption of a ‘western’ type lifestyle in Asian 
countries has led to an even larger global increase in IBD diagnoses16.  Evidence supports a 
combination of genetic susceptibility, environment, intestinal dysbiosis, and/or over-activation of 
intestinal immune cells being responsible for IBD pathogenicity2,5.   At present, no cure exists, 
which emphasizes the need for further study of IBD and more specifically IBD pathogenicity. 
Intestinal Homeostasis 
Before discussing the details of how alcohol and colitis affects the intestines, it is 
important to first understand the structure and functions of the tissues and cells within the 
intestinal tract. The spatial relationships established between the lumen and barrier of the gut are 
absolutely essential for the proper function of the gastrointestinal (GI) tract in digestion and 
nutrient absorption.  The GI tract is a continuous tube that begins at the stomach and ends at the 
anus.  The focus of this research is confined UC and, thus, to the large intestine (colon).  The 
colon is composed of four regions proximally to distally: the ascending, transverse, descending 
and sigmoid colon, respectively, and terminates with the rectum and anus.  The large intestines 
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are held in place to prevent twisting by the mesentery, which also contains the mesenteric lymph 
nodes (MLNs).  The small and large intestines at the histological level contain a barrier of 
mucous and epithelial cells that block the translocation of lumenal bacteria to extra-intestinal 
sites.  Just below the intestinal epithelia lies a layer of loose connective tissue, the lamina propria 
(LP), which connects the surface mucosal epithelium to the basement muscularis mucosae.  The 
LP also contains a large number of the intestinal immune cells.  The immediate proximity of the 
intestinal immune cells and the bacteria within the lumen present a major challenge for 
homeostatic regulation.  Thus, the interactions between the immune cells, intestinal barrier, and 
the lumenal microbiome are of major interest in all areas related to pathology associated with the 
intestines.  
The intestinal physical barrier consists of a layer of mucus and epithelial cells that line 
the lumen of the intestines, and provide a crucial first line of defense against pathogens. Starting 
from the lumen, the first component of the physical barrier is a mucus layer. Mucus provides 
protection from the luminal bacterial content, and also lubricates the intestinal walls for passing 
bile17-20. Immediately below the mucus inflammatory host immune cells with lumenal bacterial 
antigens. Disruptions in either the intestinal mucus or epithelial barrier can result in pathogenic 
bacterial translocation, which can lead to systemic infections, sepsis, and multiple organ failure, 
underscoring the importance of maintaining barrier integrity21-23. The mucus layer is a key 
component of the physical barrier of the intestine, and is formed by a glycoprotein, mucin 
(mainly mucin-2 in rodent intestine), which is secreted by goblet cells found in the intestinal 
epithelial layer24. Mucin contains a glycosylated peptide backbone, which causes the mucus layer 
to be incredibly viscous and effective at preventing pathogen penetration25. The mucus layer is 
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not impenetrable however, and the tight junction complexes between the epithelial cells below 
the mucosa play a crucial role in providing a second level of protection.  
The intestinal wall is lined with a layer of columnar epithelial cells that serve many 
functions key to maintaining gut homeostasis.  First, intestinal epithelial cells (IECs) aid in the 
absorption and metabolism of nutrition ingested by the host26. IECs contain microvilli on their 
apical surface to drastically increase the surface area of the intestines, which aid in their 
absorptive capacity27. IECs also maintain a barrier between the lumen of the intestine and extra-
intestinal sites. While many epithelial cells serve these primary roles, there also exist several 
populations of specialized IECs. Goblet cells are mucus-secreting cells that lay down the mucin 
layer that lines the intestinal lumen24. Paneth cells are specialized anti-microbial peptide (AMP) 
secreting cells that aid in regulating the microbiome28-30. 
Finally, enteroendocrine cells are a diffuse population of cells that play a major role in 
sensing the intestine luminal content.  These cells have apical physiochemical receptors that 
signal the release of peptides and hormones from their basolateral surfaces to mediate autocrine 
and/or paracrine signaling31. All of these specialized epithelial cells must be renewed during the 
turnover of intestinal epithelial cell generation. Tight junctions are multi-protein complexes 
consisting of transmembrane, scaffold, and adaptor proteins, and play an indispensable role in 
the maintenance of barrier function32.  The proteins of tight an indispensable role in the 
maintenance of barrier function32.  Tight junctions form a paracellular seal and function as a 
selectively permeable barrier between adjacent epithelial cells.   
Tight junctions consist of several transmembrane proteins including occludin, junctional 
adhesions, and claudins33.  While the function of occludin is currently unknown,it is understood 
that it does not mediate tight junction formation, but appears to be instrumental in the regulation 
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of the junctions18,34,35. Claudins are a family of proteins that are both tissue and cell type specific, 
and are considered to be the main structural components of the tight junctions.   
In addition to the physical barrier, the intestine requires an immune barrier, which must 
distinguish between commensal and pathogenic bacteria so that it does not mount a damaging 
autoimmune inflammatory response. The immune cells that carry out these tasks comprise parts 
of both innate and acquired immune functions. They can be found in all areas of the intestines, 
especially in regions of gut associated lymphoid tissue (GALT). GALT includes the gut 
epithelium, PPs, MLNs, and LP36,37. Intestinal T cells are found in GALT sites and exist closely 
with antigen presenting cells (APCs), such as DCs and macrophages, that aid in T cell 
differentiation and activation. T lymphocytes form a large part of the adaptive immune response 
in the intestine. Under homeostatic conditions, the balance between inflammatory and 
immunosuppressive T cells is maintained through cell-to-cell cytokine signaling. Although the 
intestines contain a large and diverse population of T lymphocytes, the major subsets of resident 
T cells within the gut include Th1, Th2, Th17, and T-regulatory (Treg) cells38. The default T cell 
response in the intestines under normal conditions is immunosuppressive. This occurs through 
the production of TGF-β, primarily by APCs, which drives Treg development. In addition to 
TGF-β, IL-4 production drives Th2 cell development and B cell IgA antibody production. IgA 
also maintains gut homeostasis, in part by regulating the microbiome39. 
Inflammatory Bowel Disease Pathogenicity 
Epidemiological evidence for a genetic contribution in risk of IBD diagnosis has been 
identified.  The largest genetic association study, which employed genome-wide association data 
for over 75,000 patients and controls, identified 163 susceptibility loci for IBD.  Of these 163 
loci, 110 conferred risk to both IBD subtypes, whereas 30 loci where unique to CD and 23 loci 
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were unique to UC.  More recently, a trans-ethnic analysis including over 20,000 individuals of 
European and non-European ancestry identified an additional 38 new IBD loci, highlighting 
shared genetic risk across populations and increasing the number of known IBD risk loci to 
20040-42. 
Genetic predisposition, however, cannot be solely responsible for disease etiology, as 
genetics cannot account for the rapid rise of IBD incidence in certain geographic regions43,44.  
Several environmental factors, such as smoking, appendicitis, oral contraceptives, diet, 
breastfeeding, infections/vaccinations, antibiotics, helminths, and childhood hygiene, have been 
implicated in the increased worldwide incidence of IBD45. These factors pose serious risks, but 
are limited in their scope as they do not address microbial changes or break in tolerance of 
intestinal immune cells that could be contributing to IBD diagnoses.  Thus, further studies are 
necessary to better understand the environmental causes of IBD.  
A general consensus exists that IBD is associated with compositional and metabolic 
changes in the intestinal microbiota.  Multiple studies have documented differences in the 
composition of the gut microbiota between patients with IBD and healthy individuals, 
particularly with respect to microbial diversity and the relative abundance of specific bacterial 
taxa. Both expansion of potential pathogens and global changes in composition have been 
described. Species from the phylum, Firmicutes, specifically Faecailbacterium prausnitzii, are 
often reduced in the feces of patients with Crohn's disease46-55. Conversely, members of the 
Proteobacteria phylum, such as Enterobacteriaceae56,57, including Escherichia coli50,58,59, are 
commonly increased in patients with IBD relative to healthy individuals.  Similarly, a specific 
association between Fusobacterium nucleatum, ulcerative colitis and the development of 
colorectal cancer has been proposed based on the isolation of a highly invasive strain from 
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patients with ulcerative colitis.  Intestinal inflammation as a consequence of IBD can create an 
oxidative microenvironment, which can promote the growth of aerotolerant taxa such as 
Proteobacteria and Actinobacteria.  Interestingly and in regards to our laboratory’s current 
studies, the mouse pathogen, Citrobacter rodentium, has been shown to gain a fitness advantage 
by promoting epithelial aerobic respiration and increasing oxygenation of the mucosal surface60.  
Alterations in intestinal microbial composition have long been associated with chronic 
inflammation, but it is important to recognize that the relationship between dysbiosis and IBD is 
probably complex and dynamic, rather than one of simple cause–effect. Dysbiosis can promote 
the growth of invasive pathogenic bacteria and also can facilitate bacterial translocation through 
the intestinal mucosal barrier to extra-intestinal sites. These two phenomena contribute to the 
breakdown of epithelial barrier integirty, which is the prerequisite for the activation of the 
mucosal immune response. 
It has been established that the recognition of commensal-derived antigens by the 
adaptive immune system or its stimulation by the innate immune system play a key role in the 
pathogenesis of IBD.  Dendritic cells (DC) are at the interface between intestinal epithelial cells 
and T cells. They present antigens to naive CD4+helper T cells (Th0) and ensure tolerance to 
commensal flora by promoting differentiation of regulatory T cells (Treg). In times of infection, 
activated DCs produce pro-inflammatory cytokines and promote the differentiation of effector T 
cells, which triggers a local persistent inflammation61. The interplay between secreted pro- and 
anti- inflammatory cytokines determines the balance of different types of T cells in the intestinal 
mucosa62. In IBD, an overactivation of DCs was observed at sites of inflammation63, which 
consequently induces a strong differentiation of effector lymphocytes (CD4+ and CD8+) and of 
other effector cells such as natural killer (NK) and NK T (NKT) cells while abolishing the 
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production of regulatory cells.  Therefore, in active IBD, the balance of Th and Treg cells is 
skewed to that of increased Th and decreased Treg64.  In the mucosa of patients with UC, there is 
mostly an infiltration of Th2 lymphocytes65.  Moreover, others studies have pointed to Th17 
lymphocytes contributing to the shift towards effector T cells over regulator T cells populations 
in IBD66 Th17 lymphocytes (CD4+ CD25−) are T cells which produce the proinflammatory 
cytokine IL17, especially in response to the presence of extracellular bacteria. 
Current Definitions of Alcohol Abuse 
Alcohol (ethanol) abuse represents a major source of health and economic burden in 
society. Misuse of alcohol can take several different forms, as defined by the National Institute 
on Alcohol Abuse and Alcoholism (NIAAA). Binge drinking, the most common form of alcohol 
misuse, is defined by any pattern of drinking that raises one’s blood alcohol content to 0.08 g/dL 
or higher67. This is more generally described as four drinks for women, or five drinks for men in 
a two-hour period67. Chronic alcohol misuse, or heavy drinking, is defined as binge drinking five 
or more days per month67. Definitions of alcohol use disorders are fluid as researchers and 
clinicians re-evaluate what constitutes healthy versus unhealthy drinking behavior.  
Intestinal Pathophysiology with Alcohol Use 
Alcohol consumption alone deleteriously affects the intestinal tract as it breaks down the 
normal physical and immunological barrier provided by intestinal epithelial cells and gut 
associated lymphoid tissue (GALT), respectively10,22,68,69.  Alcohol induced intestinal erosion 
impairs intestinal absorption leading to increases in diarrhea and intestinal permeability, allowing 
for leakage of endotoxins into the circulation68,70,71.  Ethanol induced increases of both pro-
inflammatory cytokines and chemokines have been found in both the small and large intestinal 
tract following exposure to alcohol72.  The intestinal epithelium and gut associated lymphoid 
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tissue (GALT) create both a physical and immunological barrier restricting the passage of 
potential harmful toxins, such as those from intestinal bacteria, from the luminal space to extra-
intestinal sites73,74.  T and B cells, macrophages, dendritic cells of the Peyer’s patches (PP), 
mesenteric lymph nodes (MLN), and lamina propria (LP) of the gut associated lymphoid tissue 
(GALT) make up the intestinal immune barrier.  The key components of the physical intestinal 
barrier include tight junctional complexes, adherens junctions, and desmosomes between 
intestinal epithelial cells (IECs).  In particular, tight junctional complexes of the small and large 
intestine are made up of the proteins: claudin, occludin, and zonal-occludin.  These proteins are 
imperative to the maintenance of the physical intestinal barrier prohibiting translocation of 
bacteria out of the lumen while allowing the selective absorption of critical nutrients required by 
the host.  Any perturbation to this tightly regulated intestinal barrier could lead to a so called 
‘leaky-gut’, with deleterious effects not only at the level of the gastro-intestinal tract, but also 
allow bacterial endotoxin to penetrate the mucosa and enter systemic circulation.  Alcohol 
consumption alone is known to disrupt the functional and structural integrity of intestinal 
epithelial cells contributing to increased gut leakiness by a variety of mechanisms75-77.  Firstly, as 
increases in ROS following ethanol exposure contributed to disruptions in hypothalamic 
homeostasis, ethanol-induced increases in ROS also led to disruptions in intestinal homeostasis.  
Researchers have attributed increases in gut leakiness following ethanol treatment to increases in 
oxidative stress, specifically by nitric oxide (NO).  At basal levels, NO is involved in 
maintaining normal intestinal barrier function78.  However, when NO is in excess, as is found 
after chronic exposure to alcohol, it results in barrier disruption culminating in increased gut 
leakiness79.  Secondly, alcohol use can result in intestinal barrier structure defects via damage to 
the mucosa observed as loss of epithelium at the apexes of villi, hemorrhagic erosions, and 
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hemorrhage in the lamina propria80.  Thirdly, the human intestines are home to an estimated 100 
trillion bacteria81. These microbes are involved in functions including digestion, metabolism, and 
development of host-immune defense. While the intestinal microbiome of an individual varies 
depending on a multitude of factors (diet, age, race, geographic location, etc.), the general 
balance of the major phyla that make up the majority of the intestinal microbiome is fairly 
similar. Not surprisingly, new technologies such as deep 16S ribosomal sequencing have allowed 
scientists to gain a much better understanding of the makeup of the intestinal microbiome, and 
how it varies between a healthy individual and during a diseased state81. Alcohol use has been 
demonstrated by a number of groups to drastically change the makeup of the intestinal 
microbiome82. Specifically, data show a general reduction in the ratio of the most prevalent 
phyla, Firmicutes and Bacterorides groups, which generally make up about 85-90% of the 
bacteria within the gut82-84. Additionally, a relative increase in the ratio of Gram-negative 
Proteobacteria occurs following both acute and chronic alcohol consumption, which may lead to 
increased inflammation in the intestines and other sites following intoxication82-84. It is important 
to note that not all alcohol consumption is detrimental to microbial populations within the 
intestine. A study performed by Queipo-Ortuno et al. showed that people that consumed large 
glass of red wine (272 mL) every day for 20 days had significantly increased Proteobacteria, 
Fusobacteria, Firmicutes and Bacteroidetes. Conversely, those who consumed gin (100 mL) per 
day had a significant decrease in the same phyla85. These data suggest that both the amount and 
type of alcohol consumed can influence the intestinal microbial communities and this may have a 
significant impact on the stress and inflammatory response.   
 This dysbiosis compounded with the destructive nature of alcohol on the integrity of the 
intestinal epithelium could allow for bacterial translocation out of gut and into the circulation 
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resulting in systemic inflammation.   Finally, alcohol has a stimulatory effect on neuroendocrine 
hormones, such as corticotropin-releasing hormone (CRH), which can directly lead to increased 
gut permeability86.  Increases in CRH within the gut microenvironment can lead to degranulation 
of mast cells87,88.  This degranulation triggers the synthesis and paracrine-like secretion of 
mediators to gut epithelial cells resulting in epithelial cell F-actin rearrangements increasing gut 
permeability88.   
These increases in gut permeability following alcohol consumption allow both bacteria 
and bacterial products including LPS to translocate outside the lumen and into the 
circulation72,89.  LPS that has breached the gastro-intestinal barrier induces the synthesis and 
release of IL-1β from mononuclear myeloid cells into the circulation90.  Furthermore, circulating 
LPS has been found to increase the pro-inflammatory cytokine, TNF-α, in brain, liver, and 
serum after one hour91.  As a compensatory mechanism to increases in pro-inflammatory 
cytokines, there exists anti-inflammatory cytokines such as IL-10, which is known to down-
regulate expression of Th1 pro-inflammatory cytokines.  However, when LPS leaks into the 
circulation as result of increased gut permeability following exposure to alcohol, IL-10 levels are 
decreased both in brain and intestinal tissues91.   
Therefore, the addition of alcohol could further perturb the already disrupted intestinal 
barrier in UC, acting to shift a state of disease remission to that of an active disease UC flare 
period.  
Ulcerative Colitis and Alcohol Use 
Doctors are recommending limitations on UC patient’s diets, such as refraining from 
certain foods, and, in the context of our lab’s research interest, refraining from alcohol.  Doctor’s 
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recommendations of avoiding alcohol are based in the idea that alcohol could potentially worsen 
UC symptoms2,5.  However, the scientific evidence in support of this idea is severely lacking.   
Regardless of whether or not patient’s heed this advice, they are prescribed medications 
designed to firstly push their UC into a state of remission, and then secondly to maintain the 
asymptomatic remission state.  Drugs such as 5-ASA, Infliximab, and/or antibiotics or some 
combination thereof are three of the most commonly prescribed to UC patients.  Both 5-ASA and 
Infliximab are anti-inflammatory through PPARγ activation and anti-TNFα, respectively12,14,92-94.  
Treatment of UC with broad-spectrum antibiotics, such as metronidazole and ciprofloxacin, are 
used to suppress symptoms of diarrhea and fever caused by intestinal infections. 
Of the few studies that have been conducted on IBD and alcohol, three have found a 
correlation of IBD and alcohol use. The first by Jowett et al. was an observational prospective 
study in which patients with UC remission were followed for one year to determine the effect of 
diet on relapse.  Patient symptoms were assessed by a validated disease activity index and self-
reported dietary habits, such as alcohol use. and the outcome was either clinical relapse or 
continued remission over the year. They found that patients who drank alcohol during a period of 
IBD remission experienced increased incidences of relapse into active disease95. 
The second was done in a cohort of 129 patients with IBD: 52 with Crohn's disease, 38 
with ulcerative colitis, and 39 with irritable bowel syndrome (IBS).  All participants completed 
multiple questionnaires.  The first was on disease activity (the Crohn's disease activity index or 
ulcerative colitis clinical activity index, respectively), and a second questionnaire to quantify 
alcohol consumption by National Institute of Alcohol Abuse and Alcoholism criteria.  Lastly, 
patients were given a questionnaire designed by the researchers to access patients' perception of 
the effect of alcohol on their GI symptoms and on overall GI symptom severity.  This study 
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found that 75% of patients with active IBD reported worsening of their gastrointestinal 
symptoms upon drinking alcohol69.   
Another large study by Hsu et al. reported that of the 300,000 patients without IBD they 
retrospectively analyzed over a 10-year period, patients who were at some point hospitalized for 
alcohol use had a 3.17 fold increase in risk of being diagnosed with IBD compared to the non-
alcohol intoxication cohort96.  Taken together, these three studies act as strong correlative 
evidence between alcohol and risk of UC.   
Conversely, another group of researchers at the Imperial College of London performed a 
prospective study on EU citizens, 198 UC and alcohol cases/792 controls and 84 CD and alcohol 
cases/336 controls were included.  Results from this group show no association between risk of 
IBD and alcohol use97.  However, Bergmann et al. only surveyed alcohol consumption at the 
time of enrollment, and the habits of patients could have changed over the course of the study.  
Due to the contradictions between these studies, we sought to establish a mouse model of 
UC and binge alcohol consumption, thus allowing us to fully elucidate alcohol’s potential role in 
risk of UC.  
IL-22 Responses in IBD 
During times of recovery into asymptomatic UC remission, colonic IL-22 expression is 
induced in attempt to maintain intestinal homeostasis98-100.  IL-22 is a member of the IL-10 
cytokine family, and is produced by many immune cells including CD4+ T-cells (specifically 
Th-17 and Th-22 subsets), γδT-cells, natural killer (NK) cells, innate lymphoid cell class III 
(ILC-3), and lymphoid tissue inducer (LTi)-like cells101,102.  The release of IL-22 from T-cell 
subsets is dependent upon the transcription factor aryl-hydrocarbon receptor (AhR).  Recent 
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studies have also demonstrated that IL-22 secretion from Th-17 cells is dependent upon the 
presence of IL-23, but not IL-17103.   
IL-22 is unique in that its receptor expression is relegated to cells of non-hematopoietic 
origin, such as IECs103.  The IL-22 receptor is a heterodimer composed of an IL-10Rβ and an IL-
22R subunit, and is highly expressed within the intestines.  Upon binding to its receptor, IL-22 
mediates many different effects in the intestines from enhancing mucus secretion in goblet 
cells104, to promoting anti-microbial protein release from Paneth cells105, to upregulating IEC 
proliferation106. 
Downstream signaling of the IL-22 receptor is mediated mainly through the signal 
transducer and activator of transcription (STAT)-3 molecule.  STAT3 is activated by 
phosphorylation from Jak1 and Tyk2107.  Following phosphorylation, STAT3 forms a 
homodimer and translocates to the nucleus where it mediates transcription of anti-apoptotic 
genes such as members of the Bcl-2 family108.  Understanding, how IL-22 signaling through the 
phosphorylation of STAT3 will be critical in our elucidation of the mechanism behind which 
alcohol could potentiate increases in UC symptoms. IL-22 is known to induce intestinal defenses 
of intestinal epithelial cell (IEC) proliferation and mucus production, increase levels of the anti-
inflammatory cytokine IL-10, and induce secretion of antimicrobial peptides (AMPs); all of 
which could potentially counteract the dysregulation of IEC function, increased inflammation, 
and dysbiosis present during an UC flare period100,109-113.  Therefore, IL-22 is critical for 
entrance into an UC period of remission, and a recent study found that administration of IL-22 
ameliorated UC disease symptoms113.  If any IL-22 mediated intestinal repair mechanisms are 
impaired during an UC remission period, then an UC flare period could persist.  We have 
recently observed that mice exposed to our model of binge alcohol consumption following DSS-
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induced colitis are unable to mount proper colonic IL-22 responses.  Such alcohol induced 
decreases in colonic IL-22 levels could impair IL-22 mediated intestinal tissue repair and defense 
mechanisms required for maintenance of gut barrier integrity, thus allowing for intestinal 
bacteria and bacterial endotoxins to gain access to extra-intestinal sites resulting in subsequent 
complications.  
Probiotics in Treatment of Ulcerative Colitis 
This rationale for probiotics as a viable treatment option for UC patients is 2-fold. First, 
as discussed above, UC pathogenesis is tripartite: genetic predisposition, microbial dysbiosis, 
and overactive intestinal immune system.  Damage to the intestinal barrier during UC can permit 
pathogenic luminal bacteria to initiate a mucosal inflammatory response that never ceases. 
Probiotic treatment could bacteriological milieu of the gut to allow for increases in less 
pathogenic and more anti-inflammatory bacterial species, which could abrogate mucosal 
inflammation114,115. The second consideration is that UC is a mucosal disease, so a therapy that 
works at the level of the mucosa should be beneficial.   
While antibiotics tend to be most effective in Crohn’s colitis, ileocolitis, and pouchitis, 
they are less effective in UC116-118. Probiotics by definition are preparations of living microbial 
cells that, when ingested, are believed to influence the composition of the gut microbiota and 
consequently benefit the health of the host119,120. Probiotics have been shown to reduce colitis in 
animal models121-123 and to help treat acute, and maintain remission of, UC in humans124-130. One 
probiotic, Escherichia coli is a nonpathogenic strain of E. coli that has been shown to be 
effective for both inducing remission in patients who have UC and maintaining remission for at 
least 1 year. Researchers have compared E. coli Nissle to 5-ASA, which is the standard treatment 
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for UC, and E. coli Nissle was found to be just as effective as 5-ASA for both inducing and 
maintaining remission over a 1-year period125.  
Probiotics alter the function of the mucosal immune system to make it more anti-
inflammatory and less pro-inflammatory; specifically, probiotics can stimulate dendritic cells to 
make them less responsive and reactive to bacteria within the lumen. Additionally, a probiotic 
preparation consisting of a mixture of Bifidobacterium breve, B. longum, B. infantis, 
Lactobacillus acidophilus, L. plantarum, L. paracasei, L. bulgaricus, and Streptococcus 
thermophiles (VSL#3), which are eight lactic acid bacterial species (VSL#3) has been reported to 
be effective in maintenance of remission of UC128.  
 The probiotic, Lactobacillus delbrueckii, has recently been shown to activate the 
transcription factor aryl hydrocarbon receptor (AhR), which can induce expression of IL-22.  
Takamura et al. found that treatment with Lactobacillus delbrueckii in an experimental model of 
colitis resulted in amelioration of colitis by activating the AhR pathway.  Lactobacillus 
delbrueckii induced the mRNA expression of cytochrome P450 family 1A1 (CYP1A1), a target 
gene of the AhR pathway, which was inhibited by the addition of an AhR antagonist131,132.  
These data make Lactobacillus delbrueckii an exciting therapeutic option to determine whether 
probiotic treatment could potentially reverse exacerbated UC symptoms as a result of alcohol 
use.  
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CHAPTER THREE 
GENERATING THE MOUSE MODEL OF BINGE ALCOHOL CONSUPTION FOLLOWING 
DSS-INDUCED COLITIS, WHICH PERPETUATES UC FLARE SYMPTOMS 
 
Abstract 
Inflammatory Bowel Disease (IBD) remains a prominent medical concern affecting over 
one million people in the United States alone.  While IBD’s exact cause remains elusive, the two 
most common forms of the disease are Crohn’s disease (CD) and ulcerative colitis (UC).  UC is a 
cyclical, life-long illness characterized by disease remission and active disease flares causing 
symptoms of abdominal pain, increased weight loss, intestinal inflammation, rectal bleeding, and 
dehydration.   
In order to avoid worsening of symptoms, UC patients will often head doctor’s advice to 
refrain from drinking alcohol.  However, there exists a gap in scientific evidence as to whether 
this phenomenon of alcohol exacerbating UC symptoms truly does occur.  The current study 
sought to establish a mouse model of UC along with a binge alcohol paradigm in order to 
advance research in this area.  To accomplish this, male C57BL/6 were given either 2%, 3%, or 
4% dextran sodium sulfate (DSS) in their drinking water for 7 days. Mice in Sham/control group 
received water. Additionally, one group of 3% DSS treated mice were given a three-day binge of 
alcohol via gavage at ~3g/kg. Three hours after the last gavage on day 7, mice were humanely 
euthanized. Body weight was regularly monitored over the course of the 7 days and colon length 
was measured on day 7 after sacrifice.  Although the first trial of the model was promising in that 
the addition of alcohol to the group of mice given 3% DSS had increased weight loss compared 
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to 3% DSS vehicle treated mice, the data was unrepeatable.  Therefore, we changed out 
experimental model to give either a 2% or 3% solution of DSS for only five days, instead of 
seven. Mice in Sham/control group received water.  On day five, mice were further subdivided 
into two groups: mice receiving only one gavage of alcohol (~3g/kg) on day 7 or a three-day 
binge of alcohol on days 5, 6, and 7.  In all cases, three hours after the last gavage on day 7, mice 
were humanely euthanized. Body weight was regularly monitored over the course of the 7 days 
and colon length was measured on day 7 after sacrifice.  Regardless of whether mice received 
DSS at a 2% or 3% concentration, when only one gavage of alcohol was given, there were no 
significant differences in weight loss or colonic shortening.  However, the group of mice 
receiving a 2% DSS concentration in their drinking water for five days in addition to a binge 
alcohol paradigm of alcohol gavage for 3 days had significantly increased weight loss 
(***p<0.001) and colon shortening (*p<0.05) compared to 2% DSS vehicle treated mice.  
Increased weight loss and colonic shortening are the two critical parameters in the field of 
UC research to accurately monitor UC disease severity.  As statistical significance was reached 
with the 2% DSS concentration along with a three-day binge alcohol paradigm for both of theses 
parameters, these data suggest that this was the best applicable mouse model to begin our lab’s 
research of the hypothesis that alcohol – known to be both pro-inflammatory and directly 
harmful to gut barrier function – could exacerbate a UC flare period. Body weight was regularly 
monitored over the course of the 7 days. Colon length was measured and large intestines 
harvested for histopathology, clinical scores, and quantification of IL-18, IL-1β, IL-6, TNFα, 
and KC proteins levels via ELISA. Consistent with previous reports, mice treated with DSS 
began losing body weight on day 5 after treatment as calculated by percent weight change from 
day 0.  On day 6, mice receiving a combined insult of DSS and alcohol lost twice as much 
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weight compared those mice in the DSS Vehicle group, ~10% vs. ~5% respectively.  By day 7, 
the weight loss in mice receiving DSS and alcohol reached 17% to that of their original body 
weight as compared to only 12% in DSS Vehicle mice.  Gross histopathology scores were 
significantly increased in the DSS Ethanol group compared to DSS Vehicle.  
This accompanied a significant decrease in colon length in the DSS Vehicle group of mice 
(p<0.0001) compared to that of Sham Vehicle mice.  Interestingly, the addition of alcohol to the 
DSS treated mice resulted in a more severe decrease in colon length (p<0.05) compared to DSS 
Vehicle treated mice.  Clinical scores of the DSS Ethanol treated mice trended toward an 
increase compared to the DSS Vehicle mice.  
Furthermore, the levels of the pro-inflammatory cytokines, IL-18 and IL-1β, trended to 
increase in the large intestine of mice receiving DSS and alcohol.  IL-18 increased by ~6 fold in 
the DSS Vehicle group when compared to Sham Vehicle mice (p<0.01).  Adding alcohol to the 
DSS treated mice, further increased levels of IL-18 to ~10 fold compared to the Sham Vehicle 
group of mice (p<0.001).  IL-1β increased ~80 fold (p<0.0001) in mice receiving DSS Vehicle 
compared to Sham Vehicle mice, but there was no further increase in IL-1β with the addition of 
alcohol. Both IL-6 and TNFα increased by ~3 fold in DSS Vehicle, but were not further 
increased with the addition of alcohol. KC also increased ~3 fold in DSS Vehicle treated mice 
compared to Sham Vehicle, but the addition of alcohol increased KC to that of ~4 fold compared 
to Shame Vehicle.  These data suggest that alcohol perpetuates a DSS-induced colitis flare 
period resulting in increased weight loss, colonic shortening, histopathology and clinical scores, 
and inflammation.  
Introduction 
Inflammatory Bowel Disease (IBD) is diagnosed in over 1.4 million Americans each 
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year. Yet, the exact mechanisms behind disease onset remain elusive1,2. IBD is subdivided into 
two clinical categories of either Crohn’s disease (CD) or Ulcerative Colitis (UC), characterized 
by inflammation of the entire gastrointestinal tract in CD or the large intestine only in UC1. UC 
accounts for over 700,000 IBD diagnoses and is most prevalent in patients under thirty; the age 
range where an estimated 70% of binge alcohol drinking episodes occur1-3,5,15. UC is a life-long 
disease characterized by cycles of asymptomatic remission and active disease flares. UC patients 
are subject to symptoms of bloody stool and subsequent anemia, bowel incontinence, and weight 
loss2.  
The precise etiology of UC is still unknown, but research has focused on genetic factors 
leading to over activation of the immune system with a break in tolerance to commensal 
intestinal bacteria, environmental factors resulting in dysbiosis of the bacterial population 
residing in the gut, or some combination thereof that could potentially be contributing to disease 
onset. As there is no cure for UC, patients are forced into maintenance regimens obtaining 
symptomatic relief through the use of immunosuppressive drugs, antibiotics, or surgical 
therapies2,12,14.  This maintenance of UC requires patients to avoid stress, certain foods, and 
alcohol, as all three can potentially induce flare periods of UC2,133. Specifically, physicians 
recommend UC patients maintain a sober lifestyle133, but there exists a gap in knowledge as to 
how alcohol intoxication affects UC flare periods.  
Alcohol consumption is well known to be both pro-inflammatory and directly harmful to 
gut barrier function as it breaks down the normal physical and immunological barrier provided 
by intestinal epithelial cells and gut associated lymphoid tissue (GALT), respectively10,22,69,134. 
Alcohol alone is known to induce intestinal erosion, which can impair intestinal absorption 
leading to increases in diarrhea and intestinal permeability15, allowing for leakage of bacteria or 
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bacterial endotoxins into the circulation70,71,134. Despite this, only a handful of studies have 
explored the impact of alcohol in the setting of UC. Some research has shown that alcohol has a 
deleterious role in UC by increasing gastrointestinal symptoms69, inducing a flare95 and 
promoting disease onset96, while one study describes that alcohol has no effect in the onset of 
UC97. The inconsistency of evidence in either support or contradiction of alcohol’s role in 
exacerbating UC flare and/or onset prompted us firstly to elucidate whether alcohol is a 
contributing factor in UC flare.  
Thus, we developed a mouse model of binge alcohol consumption following an induced 
colitis flare to test the hypothesis that alcohol exacerbates an UC flare.  We found alcohol 
exacerbates weight loss, clinical scores, colonic shortening and inflammation, suggesting alcohol 
as an underlying factor in perpetuating symptoms of IBD. 
Materials and Methods. 
 
Induction of DSS Colitis. 
Male 8-9 week old (~23-25g body weight) C57BL/6 mice were obtained from Charles 
River Laboratories (Wilmington, MA). Briefly, mice received either 2%, 3%, or 4% (wt/vol) 
DSS (40,000 kDa; MP Biomedicals), ad libitum, in their drinking water for seven days in 
Figures 1, 2, 3. Mice in the Sham group received water only acting as a control. The amount of 
DSS water drank per animal was recorded and no differences in intake between groups were 
observed. Mice were weighed every day for the determination of percent weight change. This 
was calculated as: % weight change = (weight at day X- weight at day 0/weight at day 0) X 100. 
Animals were monitored clinically for rectal bleeding, diarrhea, and general signs of morbidity, 
including hunched posture and failure to groom.  In figures 4 and on, on day 5, DSS was 
discontinued and replaced with normal drinking water in both the DSS and Sham/control groups.  
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Binge alcohol paradigm.  
On day 5, mice in both the DSS and Sham/control group were further subdivided two 
subgroups: mice gavaged with alcohol (~3g/kg) or mice gavaged with water.  Mice in the 
Ethanol groups received alcohol on days 5, 6, and 7 to mimic a binge alcohol abuse pattern, 
Figures 1 – 3 and 5 – 6.  In Figures 4 and 5, mice were gavaged with either alcohol (~3g/kg) or 
water on day 7 only.  
The experiments described here were carried out in adherence with the National Institutes 
of Health (NIH) Guidelines for the Care and Use of Laboratory Animals and are approved by the 
Institutional Animal Care and Use Committee, Loyola University Chicago Health Sciences 
Division, Maywood IL. 
Tissue Staining.  
For hematoxylin and eosin (H&E) staining, 2cm of colon tissue closest to the rectum was 
taken from each mouse and saved in 10% formalin. Tissue was fixed with 10% phosphate 
buffered formalin, paraffin embedded, sectioned at 5 μm, and stained with hematoxylin and 
eosin by AML laboratories (Saint Augustine, Florida). Images were taken on an Olympus BX43 
Microscope using an Olympus DP26 camera.  
Histopathology Scoring.  
H&E stained sections were analyzed and scored in a blinded manner by Dr. Xianzhong 
Ding. Dr. Ding is an Associate Professor of Pathology at Loyola University Chicago and 
member of my Dissertation Committee.  Scoring was based on a modified 0-4 point scale 
examining exudate, epithelial damage, polymorphonuclear leukocyte invasion, and submucosal 
edema20. The values from each of the 4 categories were added to produce a combined 
histopathology score for each animal. 
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Colon Length and Average Clinical Scores.  
Immediately following euthanasia, colons were excised and length measured. Baseline 
clinical scores were determined using a modified protocol from Siegmund et al.135,136. Briefly, no 
weight loss was registered as 0, weight loss of 1–5% from baseline was assigned 1 point, 6–10% 
2 points, 11–20% 3 points, and more than 20% 4 points. For stool consistency, 0 points were 
assigned for well-formed pellets, 2 points for pasty and semiformed stools that did not adhere to 
the anus, and 4 points for liquid stools that did adhere to the anus. For bleeding, 0 was assigned 
for no blood by using hemoccult (Beckman Coulter), 2 points for positive hemoccult, and 4 
points for gross bleeding.  
Enzyme-Linked Immunosorbent Assay.  
Mice in all four groups were sacrificed three hours after the last gavage on day 7, as seen 
in Figure 8. Large intestines were harvested and homogenized. The homogenates were analyzed 
for IL-18 (eBioscience), IL-1B (R&D Systems), IL-6 (R&D Systems), TNFα (eBioscience), and 
KC (BD Biosciences) using their respective ELISAs per the manufacturer’s instructions. The 
cytokine levels were expressed per milligram of total protein in the homogenates. 
Statistics.  
Comparisons within groups were analyzed using a one-Way ANOVA with a Tukey post-hoc 
test. Analysis was done using GraphPad Prism software. A confidence level of p < 0.05 was 
considered statistically significant. Significance is represented throughout the manuscript as 
follows: * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001.  
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Results 
Exploration of current UC literature shows researchers using the chemical, dextran 
sodium sulfate (DSS), in the drinking water of mice to induce and mimic symptoms of UC.  UC 
researches utilize a concentration of DSS ranging anywhere between 1-5%.  As can be seen in 
Figure 1, we explored a range of DSS concentrations, 2, 3, and 4%, for seven days to understand 
what works best in our hands and the environment of our animal facility.  
 
Figure 1. Mouse Model of Colitis Utilizing a Range of DSS from 2-4% Over the Course of                                                                                                         
Seven Days Followed by a Three-Day Alcohol Binge. 
  
We found that increasing concentrations of DSS correlate with increases weight loss and 
colonic shortening, Figure 2A and 2B, respectively. The addition of a binge alcohol paradigm 
to 3% DSS treated mice significantly increased weight loss compared to 3% DSS Vehicle mice 
(Figure 2A), but not colonic shortening, Figure 2B.  
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Figure 2. Increased Weight Loss and Colonic Shortening with Increasing Concentration of 
DSS and Addition of Ethanol. A. Increased concentrations of DSS and the addition of ethanol 
increased weight loss. Percent weight change of animals was determined by the following 
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equation: % weight change = (weight at day X-weight at day 0/weight at day 0)*100. Values are 
mean ± SEM, n=7-9 animals/group. **p<0.01 3% DSS Ethanol compared to 3%DSS Vehicle, 
***0p<0.0001 DSS Ethanol compared to Sham  Vehicle, ****p<0.0001 4% DSS Vehicle 
compared to Sham Vehicle by ANOVA on day 7. B. Increased concentrations of DSS and the 
addition of ethanol increased colonic shortening. Values are mean ± SEM, n=5-6 animals/group 
*p<0.05 2% DSS Vehicle compared to Sham Vehicle, **p<0.01 3% DSS Vehicle compared to 
Sham Vehicle, ****p<0.0001 3% DSS Ethanol compared to Sham Vehicle, ****p<0.0001 4% 
DSS Vehicle compared to Sham Vehicle by ANOVA.  
 
From data in Figure 2, we determined a 3% concentration of DSS for seven days was the 
best working concentration for our lab to move forward.  A 3% concentration of DSS is widely 
used in the field and very well established.  Next, we included proper controls in order to 
determine the optimal binge alcohol paradigm.  Disappointingly, as can be seen in Figure 3A, 
we were unable to repeat the significant increases in weight loss in 3%DSS Ethanol treated mice 
compared to 3% DSS Vehicle treated mice we saw in Figure 2A.  Colonic shortening in Figure 
3B followed the same trends as Figure 2B with no significant increases in colonic shortening 
with the addition of a binge alcohol paradigm.   
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Figure 3. No Significant Differences in Weight Loss or Colon Length in DSS Ethanol 
Treated Mice Compared to Vehicle. A. Increased weight loss with increasing concentrations of 
DSS, but not with addition of ethanol. Percent weight change of animals was determined by the 
following equation: % weight change = (weight at day X-weight at day 0/weight at day 0)*100. 
Values are mean ± SEM, n=6-9 animals/group. ****p<0.0001 3% DSS Vehicle, 3% DSS 
Ethanol, and 4% DSS Vehicle compared to Sham Vehicle; ****p<0.0001 3% DSS Vehicle, 3% 
DSS Ethanol, and 4% DSS Vehicle compared to Sham Ethanol by ANOVA on day 7.  B. 
Increased concentrations of DSS, but not the addition of ethanol, increased colonic shortening. 
Values are mean ± SEM, n=6-9 animals/group. ****p<0.0001 3% DSS Vehicle, 3% DSS 
Ethanol, and 4% DSS Vehicle compared to Sham Vehicle; ****p<0.0001 3% DSS Vehicle, 3% 
DSS Ethanol, and 4% DSS Vehicle compared to Sham Ethanol by ANOVA on day 7 
 
From these data in Figure 3, we re-evaluated our experimental design. A staple in the 
field of UC research is significant differences in both weight loss and colonic shortening in order 
to claim a worsened disease state. Furthermore, the idea that someone in an active UC flare 
(modeled by us keeping DSS in the drinking water for seven days during alcohol binge) would 
choose to engage in binge alcohol drinking needed to be addressed.  Also, the 3% concentration 
of DSS was potentially causing too much damage to the intestine to pick up the minute 
differences alcohol could be contributing to the disease state.  So, we added a lower 
concentration of DSS, a 2% solution, in addition to 3%, in addition to stopping DSS on day 5.  
Additionally, we sought to determine the optimal binge alcohol paradigm.  So, for this 
experiment we simply employed one gavage on day 7, Figure 4.  
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Figure 4. Mouse Model of Colitis Utilizing Either 2% or 3% DSS for Five Days Followed 
by a One-Day Alcohol Binge. 
 
With this model of DSS induced colitis and binge alcohol, no significant differences in 
either weight loss or colonic shortening were observed with just one gavage of alcohol on day 
seven in either the 2% DSS treated or the 3% DSS treated mice, Figure 5A and B.  
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Figure 5. No Significant Differences in Weight Loss or Colon Length in DSS Ethanol Mice 
Receiving One Gavage of Ethanol Compared to Vehicle. A. Weight loss of both 2% and 3% 
DSS treated mice with one gavage of ethanol. Percent weight change of animals was determined 
by the following equation: % weight change = (weight at day X-weight at day 0/weight at day 
0)*100. Values are mean ± SEM, n=6-9 animals/group. B. Colon length of both 2% and 3% DSS 
treated mice with one gavage of ethanol.  
 
Therefore, we employed a binge alcohol model of 3 gavages on days 5, 6, and 7 with the 
same two concentrations of DSS, Figure 6.   
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Figure 6. Mouse Model of Colitis Utilizing Either 2% or 3% DSS for Five Days Followed 
by a Three-Day Alcohol Binge. 
 
As can be seen in Figure 7A and 7B, mice treated with 2% DSS for five days and three 
gavages of alcohol experienced significant increases in both weight loss and colon shortening.  
Mice in both the 3% DSS (Vehicle and EtOH) treatment groups trended towards increased 
weight loss and colon shortening compared to the 2% DSS treated groups, but as in Figure 3A 
and B, the addition of alcohol to these 3% DSS treated mice showed no further increase in either 
parameter.  
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Figure 7. Significant Differences in Both Weight Loss and Colon Length in 2% DSS 
Ethanol Treated Mice Compared to Vehicle, Not 3% DSS Ethanol. A. Increased weight loss 
with 2% DSS and ethanol, but not 3% DSS and ethanol. Percent weight change of animals was 
determined by the following equation: % weight change = (weight at day X-weight at day 
0/weight at day 0)*100. Values are mean ± SEM, n=6-9 animals/group. ***p<0.001 2% DSS 
Ethanol compared to 2% DSS Vehicle, ****p<0.0001 2% DSS Ethanol compared to both Sham 
Vehicle and Sham Ethanol. ****p<0.0001 3% DSS Ethanol compared to both Sham Vehicle and 
Sham Ethanol. ns = not significant for 3% DSS Ethanol compared to 3% DSS Vehicle by 
ANOVA on day 7.  B. Colonic shortening increased with the addition of ethanol after 2% DSS 
treatment but not 3%. Values are mean ± SEM, n=6-9 animals/group. *p<0.05 2% DSS Ethanol 
compared to 2% DSS Vehicle. **p<0.01 2% DSS Vehicle compared to Sham Vehicle. 
****p<0.0001 2% DSS Ethanol compared to Sham Vehicle. ****p<0.0001 3% DSS Vehicle and 
3% DSS Ethanol compared to Sham Vehicle by ANOVA on day 7. 
 
Thus, our lab determined the best mouse model of DSS-induced colitis and alcohol to use 
was a 2% concentration of DSS for five days to mimic symptoms of UC in conjunction with a 
three day binge alcohol paradigm, which showed preliminary evidence that alcohol exacerbates 
UC.   
Weight loss, histopathology score, colonic shortening, and average clinical score are the 
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most common experimental observations used to assess UC disease severity. Therefore, we first 
repeated weight loss or gain in our newly adapted model of UC and binge alcohol. Consistent 
with previous reports, mice treated with DSS began losing body weight on day 5 after treatment 
as calculated by percent weight change from day 0. On day 6, mice receiving a combined insult 
of DSS Ethanol lost twice as much weight compared to those mice in the DSS Vehicle group, 
~10% vs. ~5% respectively. By day 7, the weight loss in mice receiving DSS Ethanol reached 
17% to that of their original body weight as compared to only 12% in DSS Vehicle mice, Figure 
8. 
 
Figure 8. Ethanol Increased DSS-induced Weight Loss. Percent weight change of animals 
was determined by the following equation: % weight change = (weight at day X-weight at day 
0/weight at day 0)*100. Values are mean ± SEM, n=8-14 animals/group. ***p<0.001 DSS 
Ethanol compared to DSS Vehicle, ***p<0.001 DSS Vehicle compared to Sham Vehicle; 
****p<0.001 DSS Ethanol compared to Sham Vehicle by ANOVA on day 7. 
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To address differences in histopathology between the four experimental groups, sections 
of colon were taken closest to the rectum, stained via H&E, blinded, and scored by a pathologist. 
Figure 9A shows gross differences in large intestine morphology after DSS Ethanol treatment 
compared to all other groups. Inflammatory infiltrate, epithelial damage, and crypt damage are 
severely increased in the DSS Ethanol mice compared to that of the DSS Vehicle.  Furthermore, 
combined histopathology scores in Figure 9B, show significant increases in DSS Ethanol 
compared to DSS Vehicle.  
 
A. 
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Figure 9. Gross Histological Pathologies Increased Following Combined Ethanol and DSS 
Treatment. A. Representative H&E stained sections of the colon on day 7 (Top row x100, 
Bottom row x200). B. Combined Histopathology Score following blinded histological scoring as 
described in detail in Methods section above. Values are mean ± SEM, n=4-5 animals/group. 
**p<0.01 DSS Ethanol compared to Sham Vehicle and Sham Ethanol, ; *p<0.05 DSS Ethanol 
compared to DSS Vehicle by ANOVA. 
 
Increased weight loss and histopathology scores accompanied a significant decrease in 
colon length in our novel model of UC and binge alcohol. As has been observed by many others 
in the past23, DSS Vehicle treated mice experienced a decrease in colon length compared to that 
of Sham Vehicle mice. Interestingly, the addition of alcohol to the DSS treated mice resulted in a 
more severe decrease in colon length compared to DSS Vehicle treated mice, Figure 10A. 
Clinical scores were obtained by combining weight loss, stool consistency, and blood in stool as 
described in the methods section above. Data in Figure 10B show that the addition of alcohol to 
DSS- induced colitis trends toward an increase in the average clinical score compared to DSS 
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Vehicle, highlighting alcohol’s detrimental effect on UC flares.  
 
 
 
 
S h
a m
 V
e h
ic
le
S h
a m
 E
th
a n
o l
D S
S  
V e
h i
c l
e
D S
S  
E t
h a
n o
l
0
2
4
6
8
1 0
C
ol
on
 L
en
gt
h 
(c
m
)
****
****
#A. 
S h
am
 V
e h
ic
le
S h
am
 E
th
a n
o l
D S
S  
V e
h i
c l
e
D S
S  
E t
h a
n o
l
0
1
2
3
4
A
v
e
ra
g
e
 C
li
n
c
a
l 
S
c
o
re
**
****B. 
39 
 
 
Figure 10. Increased Colon Length Shortening and Average Clinical Scores Following 
Ethanol and DSS-Induced Colitis. A. Colon length measured in centimeters (cm) on day 7. 
Values are mean ± SEM, n=8-14 animals/group. **p<0.01 DSS Ethanol compared to DSS 
Vehicle, ****p<0.0001 DSS Vehicle compared to Sham Vehicle; ****p<0.0001 DSS Ethanol 
compared to Sham Vehicle by Two-way ANOVA. B. Clinical scores as described above. Briefly 
scores were determined by the average of % body weight loss, stool consistency, and presence of 
blood in the stool. Values are mean ± SEM, n=4-6 animals/group. **p<0.01 DSS Vehicle 
compared to Sham Vehicle; ***p<0.001 DSS Ethanol compared to Sham Vehicle by ANOVA. 
  
Colonic inflammation is a hallmark symptom of UC. To further delineate how alcohol 
could be exacerbating an UC flare, levels of large intestine pro-inflammatory cytokines were 
determined. We hypothesized that alcohol would further increase levels of large intestine pro-
inflammatory cytokines following the addition of our alcohol binge paradigm. Our results 
revealed that in mice receiving DSS Ethanol, IL-18 (Figure 11A), IL-1β (Figure 11B), and KC 
(Figure 11E) trended to increase compared to DSS Vehicle treated mice. However, the 
cytokines, IL-6 (Figure 11C) and TNFα (Figure 11D) were not found to be increased in the 
colons of DSS Ethanol treated mice compared to mice receiving DSS Vehicle.  
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Figure 11. Increased Colonic Inflammation After DSS-Induced Colitis and Ethanol. Colons 
were harvested, homogenized, and processed on day 7 for the analysis of inflammatory 
mediators using respective ELISAs. A. IL-18, B. IL-1β, C. IL-6, TNFα, E. KC by ELISA. 
Values are mean ± SEM 3-6 animals per group *p<0.05; **p<0.01; ***p<0.001 all groups 
compared to Sham Vehicle by ANOVA. 
 
Although increases in inflammation following DSS Ethanol did not reach statistical 
significance, total large intestine homogenates were used for all ELISAs, and we anticipate 
specifically isolating inflamed areas in contrast to diluting inflamed areas with non-inflamed 
areas (as commonly occurs in the intestines of UC patients) will yield statistical significance. 
However, future work will focus on this and the specific cell types in the intestine responsible for 
the increases in inflammation that we do see in the total homogenates. 
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Summary 
In the current study, we were able to show that neither seven days of 3% DSS in the 
drinking water of mice plus a three day binge model of alcohol nor a 2% DSS solution with one 
alcohol gavage on day 7 showed significant differences in the UC symptoms of weight loss and 
colonic shortening.  While it is plausible that alcohol could have been mediating other increases 
in UC symptoms at the 3% DSS concentration or 2% DSS with one gavage of alcohol, we 
needed both weight loss and colonic shortening to be statistically significant between ethanol and 
vehicle treated mice to claim alcohol induces increases in symptoms of UC.    
However, we were able to show that a 2% concentration of DSS given ad libitum for five 
days in the drinking water of mice was sufficient to induce symptoms of UC.  Moreover, a binge 
alcohol paradigm of three gavages on days 5, 6, and 7 exacerbated UC symptoms of weight loss 
and colon length shortening: 2 of the most common parameters measured in the field of UC to 
assess disease severity.  Evidence from these experiments gave rise to our current and, to the best 
of our knowledge, novel murine model of UC and alcohol, which has allowed a better 
understanding of how drinking alcohol could affect UC patiens. Understanding potential 
environmental factors that could contribute to disease flares, either as a trigger or an 
exacerbation of symptoms, is critical to improving the quality of life of UC patients stuck in the 
maintenance of their disease hoping to avoid a flare or a worsening of symptoms during a flare 
period.  
We were able to show that mice undergoing a binge alcohol paradigm following DSS-
induced colitis had exacerbated symptoms of UC as shown by increases in weight loss, colon 
shortening, histopathology and clinical scores, and inflammation, all of which are standard 
assessments of UC severity in mouse models. 
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CHAPTER FOUR 
 
DECREASED LEVELS OF LARGE INTESTINE INTERLEUKIN-22 PLAY A ROLE IN 
ALCOHOL INDUCED EXACERBATION OF UC FLARE 
 
Abstract 
 
Ulcerative colitis, one of the two most common forms of IBD, is a disease characterized 
by cycles of active disease flare and inactive disease remission.  During UC remission, IL-22 
expression is upregulated, acting as a hallmark of entrance into a UC remission period as it 
stimulates proliferation, mucous protection, and AMP secretion within the intestine.  Recently, 
we found that in our mouse model of binge alcohol consumption after DSS-induced colitis, 
alcohol increases severity of UC flare symptoms.  In this study, we assessed whether alcohol 
influenced IL-22 expression and thereby perpetuates UC flare. To accomplish this, male 
C57BL/6 were divided into two groups: DSS and Sham. In DSS group, mice received 2% DSS 
ad libitum in their drinking water for 5 days to induce UC. Mice in Sham/control group received 
water. On day 5, DSS was removed from the drinking water to mimic entrance into remission.  
Additionally on day 5, DSS and Sham/control group mice were further subdivided into two 
subgroups: mice gavaged with alcohol (~3g/kg) or mice gavaged with water days 5, 6, and 7.  
Three hours after the last gavage on day 7, mice were humanely euthanized.  Large intestines 
were harvested and processed for quantification of the cytokines IL-22 and IL-17.  Furthermore, 
large intestine lamina propria immune cells were isolated for assessment of total IL-22+ cells and 
IL-22+ T cells, innate lymphoid cells type 3, and neutrophils by FACS analysis.  Protein levels 
of large intestine IL-22 were significantly decreased ~6.9 fold (p<0.05) in DSS Ethanol 
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compared to DSS Vehicle. In contrast, levels of the pro-inflammatory cytokine, IL-17, remained 
elevated in DSS Ethanol treated mice compared to DSS Vehicle.  The percentage of total IL-22+ 
lamina propria cells in the large intestine was significantly increased in DSS Vehicle treated 
mice compared to DSS Ethanol.  No differences in IL-22+ CD3+CD4+ T cells, NKp46+ innate 
lymphoid cells type 3, or GR1+ neutrophils were observed between the DSS Vehicle and DSS 
Ethanol group.  Examination of IL-22+ γδ T cells, however, revealed that DSS Vehicle treated 
mice had a significantly increased percentage of IL-22+ γδ T cells, while IL-22+ γδ T cells from 
DSS Ethanol treated mice were unable to mount this IL-22 response.  Failure to mount the IL-22 
mediated repair response needed for entrance into remission in alcohol treated mice could be a 
potential explanation for the exacerbated UC flare period.  
Introduction 
Inflammatory bowel disease (IBD) is an idiopathic gastrointestinal disease of chronic 
inflammation that takes over the intestinal mucosa, and thereby destructs both the structure and 
function of the gastrointestinal tract.  IBD encompasses a multitude of GI inflammatory 
conditions, but the two most prevalent are Crohn’s Disease (CD) and Ulcerative Colitis (UC)3.  
CD affects the entirety of the GI tract, while UC is restricted to the colon with inflammation 
emanating from the rectum and advancing to the rest of the colon.  During UC microbial 
dysbiosis can drive pathogenicity, but there also exists an improper mucosal immune response to 
the altered intestinal microbiota58. This dysbiosis has profound effects on the immune system and 
intestinal health.  The altered microbial composition changes the balance between T regulatory 
cells (Treg) and T helper cells (Th) cells in the lamina propria conditioning an inflammatory 
state137,138.  This inflammatory state is termed active UC flare.  UC cycles between active flare 
periods and periods of asymptomatic disease remission.  A recent series of clinical studies have 
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shown that complete regeneration of the intestinal mucosa, called “mucosal healing”, predicts 
long-term remission and low risk of surgical treatment in IBD patients139. 
Interleukin (IL)-22 is a key cytokine that links intestinal immune activation to epithelial 
repair and barrier protection following damage103,140. IL-22 is expressed by numerous immune 
cells, including T helper cells, γδ T cells, type 3 innate lymphoid cells (ILC3), natural killer 
(NK) cells, and neutrophils.  Intestinal epithelial cells express the IL-22R complex, and binding 
of IL-22 results in the induction of mucins, antimicrobial peptides (AMPs), and anti-apoptotic 
pathways that collectively aid in limiting bacterial encroachment while promoting epithelial 
proliferation, wound healing, and repair141. Mice that lack the ability to produce IL-22 following 
administration of dextran sodium sulfate (DSS) or Citrobacter rodentium are grossly unable to 
repair barrier damage or control pathogenic bacterial expansion100,112,142. These data suggest that 
IL-22 plays a major function in mucosal barrier defense and repair mechanisms, which could be 
responsible for entrance into UC remission. 
In our model of DSS-induced colitis and binge alcohol, the UC flare-inducing agent, 
DSS, is removed three days before sacrifice to model entrance into UC remission. Sugimoto, 
Zenewicz, Monteleone, and others UC researchers have provided evidence that IL-22 protects 
and inhibits intestinal inflammation in the context of colitis112,141,143.  Our results show that DSS 
Vehicle treated mice can mount the proper IL-22 response within the large intestine to begin 
repair mechanisms required for UC remission.  However, the IL-22 response is disrupted in DSS 
Ethanol treated mice.  Unexpectedly, we found that the potential source of increased IL-22 in the 
large intestine of DSS Vehicle treated mice is lamina propria γδ T cells, while γδ T cells from 
mice in the DSS Ethanol group were unable to mount the proper IL-22 response.   
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Materials and Methods 
 
Induction of DSS Colitis and Binge Alcohol.  
Male 8-9 week old (~23-25g body weight) C57BL/6 mice were obtained from Charles 
River Laboratories (Wilmington, MA). Briefly, mice were randomly separated into four 
experimental groups: Sham Vehicle, Sham Ethanol, DSS Vehicle, and DSS Ethanol. DSS treated 
mice received 2% (wt/vol) DSS (40,000 kDa; MP Biomedicals), ad libitum, in their drinking 
water for five days. Mice in the Sham group received water only for 5 days acting as a control. 
On day 5, DSS was discontinued and replaced with normal drinking water in both the DSS and 
Sham/control groups. On day 5, mice in both the DSS and Sham/control group were further 
subdivided into two subgroups: mice gavaged with alcohol (~3g/kg) or mice gavaged with water 
on days 5, 6, and 7 to mimic a binge alcohol abuse pattern.  Mice were weighed every day to 
determine weight change calculated as: % weight change = (weight at day X- weight at day 
0/weight at day 0) X 100.  
Enzyme-Linked Immunosorbent Assay.  
Mice in all four groups were sacrificed three hours after the last gavage on day 7. Large 
intestines were harvested and homogenized. The homogenates were analyzed for IL-22 
(eBioscience) and IL-17 (R&D Systems).  The cytokine levels were expressed per milligram of 
total protein in the homogenates. 
Lamina Propria Cell Isolation from Colons.   
Colons were collected aseptically and placed into a collagenase D bath for 15 minutes at 
37°C, as described previously144-147. Collagenase D (0.5 mg/mL) was prepared in Hank’s 
Buffered Saline Solution (HBSS, Fisher Scientific) containing Ca2+ and Mg2+ and 
supplemented with 10 mM HEPES, 50 μg/mL gentamicin, 100 U/mL penicillin, and 5% fetal 
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bovine serum. After collagenase D treatment, the separated cell suspension was filtered through 
a 70-μm nylon filter, and washed and resuspended at a concentration of 5 × 106 cells/mL in 
complete media (RPMI 1640 supplemented with 2 mM L-glutamine, 10 mM HEPES, 50 μg/mL 
gentamicin, 100 U/mL penicillin, and 10% fetal bovine serum). 
Fluorescence Activated Cell-Sorting (FACS).  
For the measurement of large intestine T cell, innate lymphoid cell 3, and neutrophil cell 
populations mixed cells were re-suspended in fluorescence-activated cell sorting (FACS) buffer 
(phosphate buffered saline with 5% fetal bovine serum) at a concentration of 1 × 106 cells/mL. 
Cell suspensions were blocked with purified antimouse CD16/32 for 20 minutes at 4°C and 
stained with live/dead PacOrange dye to separate separate live cell populations.  Isolated cells 
were further stained with PerCP – Cy5.5 conjugated antimouse CD3, APC eFluor 780 - 
conjugated antimouse CD4, APC-conjugated antimouse NKp46, PE Cy7 conjugated – antimouse 
GR1, FITC – conjugated antimouse γδ TCR and PE-conjugated antimouse IL-22 for 30 minutes 
in the dark at 4°C.  The cells were washed twice and resuspended in 0.5-mL FACS buffer. All 
samples were analyzed at the Loyola University Health Sciences Division FACS Core Facility 
using a 7-color flow cytometer (BD FACSCanto) and FlowJo Software (Treestar).  
Statistics.  
Comparisons within groups were analyzed using a two-Way ANOVA with a Tukey post-
hoc test. Analysis was done using GraphPad Prism software. A confidence level of p < 0.05 was 
considered statistically significant. Significance is represented throughout the manuscript as 
follows: * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001.  
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Results 
 
 As seen in Figure 12, DSS Vehicle treated mice had elevated levels of IL-22 in large 
intestine homogenates, an indicator of entrance into UC remission.  By contrast, mice in the DSS 
Ethanol group show decreased levels of IL-22 compared to DSS Vehicle highlighting the 
continuance of UC flare and inability to enter into UC remission.   
 
Figure 12. Elevated Levels of IL-22 in DSS Vehicle but Not DSS Ethanol Treated Mice. 
Values are mean ± SEM 6-8 animals per group. *p<0.05 DSS Ethanol compared to DSS Vehicle 
by ANOVA; **p<0.01 DSS Vehicle compared to Sham Vehicle by ANOVA 
 
 Large intestinal levels of the pro-inflammatory cytokine, IL-17, however, remain 
elevated in both the Vehicle and Ethanol treated mice following DSS-induced colitis, Figure 13.  
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Figure 13. IL-17, a Pro-Inflammatory Cytokine, Is Elevated After DSS-Induced Colitis 
Regardless of Treatment with Vehicle or Ethanol. Values are mean ± SEM 6-8 animals per 
group. 
 
Multiple immune cells within the large intestine lamina propria (LP) are capable of 
producing IL-22, such as T cells, innate lymphoid cells, and neutrophils.  We next sought to 
determine what specific cells were responsible for the elevated levels of IL-22 we observed in 
DSS Vehicle mice, and, furthermore, what cell population or populations were impaired in their 
ability to produce IL-22 following treatment with both DSS and ethanol.  
To accomplish this, large intestine lamina propria cells were isolated and FACS sorted.  
Figure 14 demonstrates that the percentage of IL-22+ cells in the large intestine lamina propria 
in DSS Ethanol treated mice is significantly reduced compared to Sham Vehicle.  There is a 
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downward trend of decreased IL-22+ cells in DSS Ethanol compared to DSS Vehicle, but it did 
not reach significance.  
 
Figure 14. Binge Alcohol Consumption Following DSS-Induced Colitis Decreases the 
Percentage of IL-22+ cells in Large Intestine Lamina Propria. Values are mean ± SEM 4-6 
animals per group. *p<0.05 DSS Ethanol compared to Sham Vehicle.  
 
When large intestine LP lymphoid cells were sorted into CD3+CD4+ T cells, we did not 
find any difference in their percentage in DSS Ethanol group compared to other DSS Vehicle or 
sham/control mice.  However, the percentage of CD3+CD4+ T cells that were also IL-22+ was 
significantly decreased in both DSS treated groups, but not significantly different between 
Vehicle and Ethanol, Figure 15.   
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Figure 15. DSS-Induced Colitis Decreases the Percentage of CD3+CD4+IL-22+ T Cells.  
Values are mean ± SEM 6-12 animals per group. *p<0.05 Sham Ethanol compared to Sham 
Vehicle; ****p<0.0001 DSS Vehicle and DSS Ethanol compared to Sham Vehicle by ANOVA. 
 
Next, we examined a population of type 3 innate lymphoid cells (ILC3s) in their ability to 
express IL-22 as ILC3s have been implicated in the pathogenesis of ulcerative colitis.  We chose 
CD3-CD4- live lymphocytes, and then utilized the cell surface marker NKp46 to differentiate 
ILC3s, which are NKp46+.  Similar to what other researchers have observed there was a 
decrease in the percentage of IL-22+ ILC3s following DSS-induced colitis.  However, Figure 16 
demonstrates that in our model of binge alcohol consumption after DSS-induced colitis there was 
no difference in large intestine ILC3s ability to produce IL-22 after receiving alcohol compared 
to vehicle treated mice.  
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Figure 16. No Difference in Percentage of CD3-NKp46+IL-22+ ILC3s Between Vehicle and 
Ethanol Treated Mice.  Values are mean ± SEM 4-6 animals per group. *p<0.05 DSS Ethanol 
compared to Sham Vehicle by ANOVA. 
 
Another cell type known not only to be involved in the pathogenesis of UC, but also 
involved in IL-22 production is neutrophils.  Therefore, we stained our isolated large intestine LP 
cells with a common neutrophil marker GR1 and examined the percentage of neutrophils also 
expressing IL-22.  We found a significant increase in the percentage of neutrophils infiltrating 
the large intestine LP following DSS-induced colitis, but there was no difference with the 
addition of alcohol. Furthermore, the percentage of IL-22+  neutrophils was significantly 
decreased in the large intestine LP following DSS-induced colitis compared to shams but this 
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was also not found to be significantly different between the DSS Vehicle and DSS Ethanol 
treated mice, Figure 17. 
 
Figure 17. No Difference in Percentage of GR1+IL-22+ Neutrophils After Alcohol 
Consumption in DSS-Induced Colitis.  %GR1+. Values are mean ± SEM 6-12 animals per 
group. ***p<0.001 DSS Vehicle vs. Sham Vehicle and Sham Ethanol; ***p<0.001 DSS Ethanol 
vs. Sham Vehicle and Sham Ethanol by ANOVA. %GR1+IL-22+.Values are mean ± SEM 6-12 
animals per group. **p<0.01 DSS Vehicle and DSS Ethanol vs. Sham Ethanol by ANOVA. 
 
  
 
 Finally, we assessed γδ T cells, a population of T cells with a distinct T cell receptor 
(TCR) and known to produce IL-22.  Figure 18 shows that the percentage of γδ T cells in the 
large intestine lamina propria increase in both DSS Vehicle and DSS Ethanol treated mice, but 
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we did not observe any further increase with the addition of alcohol.  Interestingly, the 
percentage of IL-22+ γδ T cells was significantly increased in DSS Vehicle treated mice 
compared to both Sham Vehicle and Sham Ethanol, which mimics our results of IL-22 levels in 
large intestine homogenates in Figure 12.   Furthermore, this increase in IL-22+ γδ T cells was 
decreased in the DSS Ethanol group compared to DSS Vehicle. 
 
 
Figure 18. The Percentage of IL-22+ γδ T Cells Significantly Increased After DSS-Induced 
Colitis, but Following Binge Alcohol this Increase Was Impaired.  %γδ T cells. Values are 
mean ± SEM 6-12 animals per group . **p<0.01 DSS Vehicle vs. Sham Vehicle and Sham 
Ethanol; ***p<0.001 DSS Ethanol vs. Sham Vehicle and Sham Ethanol by ANOVA. % IL-22+ 
γδ T cells. Values are mean ± SEM 6-12 animals per group . *p<0.05 DSS Vehicle vs. Sham 
Vehicle and Sham Ethanol by ANOVA. 
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These data give evidence to the fact that the alcohol induced reduction in large intestine 
IL-22 following DSS-induced colitis could be attributed to an inability of γδ T cells to mount a 
proper IL-22 response when alcohol is present, thus exacerbating an UC flare period.   
Summary 
 The goal of this study was to understand how binge alcohol consumption could be 
perpetuating an UC flare.  The cytokine, IL-22, has been found to be a hallmark of entrance into 
UC remission.  We found that the DSS Vehicle treated mice, which were allowed to recover for 
3 days, as DSS was removed from their drinking water Day 5, had increased protein levels of IL-
22 in large intestine homogenates.  After profiling large intestine lamina propria immune cells 
known to produce IL-22, we found that DSS Vehicle treated mice had a significantly increased 
percentage of IL-22+ γδ T cells.  However, this IL-22 response both at the level of large intestine 
homogenates and γδ T cells was completely ablated in DSS Ethanol treated mice.   
 Alcohol’s role in diminishing the IL-22 response needed for entrance into UC remission 
could potentially explain the exacerbated UC symptoms we have previously observed.  
Therefore, increasing levels of large intestine IL-22 in the context of binge alcohol consumption 
and UC could act a potential therapeutic target to improve lives of UC patients.  
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CHAPTER FIVE 
 
INTERLEUKIN IL-22 ATTENUATES ALCOHOL INDUCED INCREASES IN INTESTINAL 
DAMAGE FOLLOWING DSS-COLITIS 
 
Abstract 
 
Ulcerative Colitis (UC) results in chronic inflammation and ulcers in the innermost lining 
of the large intestine and rectum. The disease process is characterized by cyclical periods of 
active illness and remission, but the exact etiology of UC flare has yet to be elucidated. 
However, UC remission periods rely on elevated levels of IL-22 to mediate intestinal tissue 
repair mechanisms. Alcohol alone induces a systemic pro-inflammatory response with 
destructive effects on the integrity of the intestinal barrier. Our lab recently observed that alcohol 
further increases symptoms of DSS-induced colitis such as weight loss, colon shortening, and 
intestinal inflammation.  Furthermore, levels of IL-22 were decreased in both large intestine 
homogenates and isolated lamina propria cells following DSS-induced colitis and alcohol. 
Therefore, we used two approaches in attempt to restore or induce large intestine IL-22 with the 
hypothesis that by re-establishing IL-22 we could alleviate the exacerbated symptoms of UC we 
observe following DSS-induced colitis and alcohol.  
First, we administered recombinant IL-22 resulting in four experimental groups: DSS 
Vehicle, DSS Ethanol, DSS Vehicle + rIL-22, and DSS Ethanol + rIL-22. Mice received DSS for 
5 days to induce UC.  On day 5, mice were divided into two groups: mice gavaged with alcohol 
or mice gavaged with water on days 5, 6, and 7.  On the evening of day 5, mice were further 
subdivided into mice receiving rIL-22 at 1mg/kg or saline via i.p. injection.  Large intestine 
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lumenal content was collected and DNA isolated for qRT-PCR analysis of Enterobacteriaceae, 
Lactobacillus, and Total Bacteria.  IL-22 administration substantially restored weight loss of 
DSS Ethanol treated mice back to that of DSS Vehicle (~12.5% back to ~6% on day 7).  
Increased colonic shortening (***p<0.001 DSS Ethanol + rIL-22 vs DSS Ethanol) and increased 
Enterobacteriaceae were also attenuated following binge alcohol and colitis with IL-22 
treatment.  Knockout of signal transducer and activator of transcription factor-3 (STAT3) in 
intestine epithelial cells resulted in loss of IL-22 protection, demonstrating STAT3 is required to 
remediate the exacerbated UC symptoms we observe following binge alcohol.  
Lactobacillus delbrueckii is a probiotic known to play a role in the activation of IL-22 
through the AhR pathway. Therefore, mice were divided into four experimental groups: DSS 
Vehicle, DSS Ethanol, DSS Vehicle + Lacto, DSS Ethanol + Lacto. Mice received DSS for 5 
days to induce UC.  On day 5, mice were divided into two groups: mice gavaged with alcohol or 
mice gavaged with water on days 5, 6, and 7. The mice were sacrificed 3 hours after the last 
gavage. Large intestine lumenal content was collected and DNA isolated for qRT-PCR analysis 
of Gammaproteobacteria, Enterobacteriaceae, Lactobacillus, and Total Bacteria.  Colons were 
harvested for ELISAs on IL-17 and IL-22 and Western Blots for STAT3 and p-STAT3. 
Treatment with Lacto attenuated both weight loss and colon length in DSS alcohol mice back to 
levels of DSS alone (p<0.01 and p<0.001, respectively).  Additionally, Lacto treatment mitigated 
the large increases in Enterobacteriaceae copy number seen in DSS alcohol treated mice.  Lacto 
treated mice trended towards a decrease of IL-17 and an increase in IL-22 in DSS alcohol mice. 
Levels of p-STAT3 were decreased in DSS alcohol treated mice compared to DSS vehicle, but 
administration of Lacto in DSS alcohol mice increased levels of p-STAT3 back to that of DSS 
vehicle group. Furthermore, treatment with Lacto supernatant alone is not sufficient to mitigate 
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the exacerbation of US following alcohol.  Instead, Lacto bacteria must be administered in order 
to see the reversal of increased UC symptoms after binge alcohol. Our findings suggest that 
Lactobacillus delbrueckii contributes to repair mechanisms by increasing levels of IL-22, 
resulting in phosphorylation of STAT3, thus attenuating the alcohol induced increases in 
intestinal damage after colitis.  
Introduction 
Inflammatory Bowel Disease (IBD) refers mainly to Crohn’s Disease and Ulcerative 
Colitis.  The etiology of both autoimmune diseases remains unknown.  However, evidence 
supports a combination of environment, genetic susceptibility, intestinal dysbiosis, and/or over-
activation of intestinal immune cells being responsible for IBD pathogenicity3,148-150.   At 
present, no cure exists, which emphasizes the need for further study of IBD and more 
specifically IBD pathogenicity.   
UC is a chronic cyclical disease with periods of active disease flares and inactive disease 
remission.  Treatment of UC focuses on keeping patients in the remission state via combination 
therapies involving anti-inflammatory drugs like Mesalazine (5-ASA), corticosteroids, or various 
other biologics5,14.  
Increased intestinal levels of IL-22 are linked to UC remission.  IL-22 protects the 
intestinal barrier by promoting mucin production, epithelial cell proliferation, and anti-microbial 
peptide secretion (e.g. Reg3β/Reg3γ)151. Downstream signaling is limited to epithelial cells as 
the IL-22 receptor, IL-22R1, is only expressed on cells of non-hematopoietic origin152. The 
primary producers of IL-22 in the intestine are type-3 innate lymphoid cells (ILC-3), and T-
helper(Th)-17 and Th-22 cells that reside in gut-associated lymphoid tissue (GALT)102. One way 
IL-22 mediates its protective effects is through the Janus kinase (Jak)/STAT pathways102. The 
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activation of STAT3, via phosphorylation, has been shown to be sufficient for IL-22 mediated 
protection in a variety of systems, including alcoholic liver disease, hepatitis, and graft-versus-
host disease153-155.   
As the previously mentioned treatments are associated with numerous side effects and 
discomfort and have yet to be studied in the context of binge alcohol, the goal of this study was 
to first examine whether administration of exogenous IL-22 could alleviate the alcohol induced 
exacerbation of UC symptoms we have previously observed.  Additionally, the probiotic, 
Lactobacillus delbrueckii, has recently been shown to activate the transcription factor aryl 
hydrocarbon receptor (AhR), which can induce expression of IL-22156.  Thus, the second goal of 
this study was to examine whether therapeutic intervention with the probiotic, Lactobacillus 
delbrueckii, modulated alcohol-induced exacerbation of UC flare.   
We further assessed whether administration of IL-22 required STAT3 signaling and 
whether treatment with Lactobacillus delbrueckii activated the IL-22/STAT3 signaling pathway 
to produce protective effects following alcohol consumption and DSS colitis. We hypothesized 
that rIL-22 treatment and/or upregulation of IL-22 by Lactobacillus delbrueckii would protect 
DSS Ethanol treated mice against the increased symptoms associated with UC flare via STAT3. 
Materials and Methods 
Induction of DSS Colitis and Binge Alcohol.  
Male 8-9 week old (~23-25g body weight) C57BL/6 mice were obtained from Charles 
River Laboratories (Wilmington, MA). Intestine epithelial cell specific VillinCre STAT3flox/flox 
knockout (henceforth referred to as “STAT3-/-”) mice were a generous gift from Dr. Bin Gao at 
the National Institute of Alcohol Abuse and Alcoholism (NIAAA), and were re-derived at 
Jackson Laboratories (Bar Harbor, ME).  All groups received 2% (wt/vol) DSS (40,000 kDa; MP 
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Biomedicals), ad libitum, in their drinking water for five days. Mice in the Sham group received 
water only for 5 days acting as a control. On day 5, DSS was discontinued and replaced with 
normal drinking water in all groups. On day 5, mice in both the DSS and Sham/control group 
were further subdivided into two subgroups: mice gavaged with alcohol (~3g/kg) or mice 
gavaged with water on days 5, 6, and 7 to mimic a binge alcohol abuse pattern. The amount of 
DSS water consumed per animal was recorded and no differences in intake between groups were 
observed. Mice were weighed every day for the determination of percent weight change. This 
was calculated as: % weight change = (weight at day X- weight at day 0/weight at day 0) X 100. 
Animals were monitored clinically for rectal bleeding, diarrhea, and general signs of morbidity, 
including hunched posture and failure to groom. 
Recombinant IL-22 (rIL-22) Treatment.  
Mice were subjected to the DSS-induced colitis and binge alcohol paradigm as described 
above. However, on day 5 mice were further divided into two subgroups: mice receiving rIL-22 
at 1mg/kg (GenScript, Piscataway Township, NJ) via intraperitoneal injection or mice receiving 
PBS on days 5 and 6. This resulted in four experimental groups: DSS Vehicle, DSS Ethanol, 
DSS Vehicle + rIL-22, and DSS Ethanol + rIL-22, Figure 19.  
 
Figure 19. Model of Treatment with rIL-22 in the Context of DSS-Induced Colitis and 
Binge Alcohol. 
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Lactobacillus delbrueckii (Lacto) Treatment.  
 
Mice were subjected to the DSS-induced colitis and binge alcohol paradigm as described 
above. However, on day four mice were further divided into two subgroups: mice gavaged with 
1 X 1011 CFUs of Lacto suspended in 300 mL of PBS or 300 mL of PBS alone on days 4, 5, and 
6. This resulted in four experimental groups: DSS Vehicle, DSS Ethanol, DSS Vehicle + Lacto, 
and DSS Ethanol + Lacto.  
 
 
Figure 20. Model of Treatment with Lactobacillus delbrueckii in the Context of DSS-
Induced Colitis and Binge Alcohol. 
 
Colon Length.  
Immediately following euthanasia, colons were excised and length measured.  
Lamina Propria Cell Isolation from Colons.   
Colons were collected aseptically and placed into a collagenase D bath for 15 minutes at 
37°C, as described previously144-147. Collagenase D (0.5 mg/mL) was prepared in Hank’s 
Buffered Saline Solution (HBSS, Fisher Scientific) containing Ca2+ and Mg2+ and 
supplemented with 10 mM HEPES, 50 μg/mL gentamicin, 100 U/mL penicillin, and 5% fetal 
bovine serum. After collagenase D treatment, the separated cell suspension was filtered through 
a 70-μm nylon filter, and washed and resuspended at a concentration of 5 × 106 cells/mL in 
complete media (RPMI 1640 supplemented with 2 mM L-glutamine, 10 mM HEPES, 50 μg/mL 
gentamicin, 100 U/mL penicillin, and 10% fetal bovine serum). 
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Fluorescence Activated Cell-Sorting (FACS).  
For the measurement of large intestine T cell, innate lymphoid cell 3, and neutrophil cell 
populations mixed cells were re-suspended in fluorescence-activated cell sorting (FACS) buffer 
(phosphate buffered saline with 5% fetal bovine serum) at a concentration of 1 × 106 cells/mL. 
Cell suspensions were blocked with purified antimouse CD16/32 for 20 minutes at 4°C and 
stained with live/dead PacOrange dye to separate separate live cell populations.  Isolated cells 
were further stained with PerCP – Cy5.5 conjugated antimouse CD3, APC eFluor 780 - 
conjugated antimouse CD4, APC-conjugated antimouse NKp46, PE Cy7 conjugated – antimouse 
GR1, FITC – conjugated antimouse γδ TCR and PE-conjugated antimouse IL-22 for 30 minutes 
in the dark at 4°C.  The cells were washed twice and resuspended in 0.5-mL FACS buffer. All 
samples were analyzed at the Loyola University Health Sciences Division FACS Core Facility 
using a 7-color flow cytometer (BD FACSCanto) and FlowJo Software (Treestar).  
Quantitative Analyses of Fecal Microbiome.  
Real-time PCR was used to quantify bacterial ribosomal small subunit (SSU) 16S rRNA 
gene abundance, as described previously157. Primers targeting SSU rRNA genes of 
microorganisms at the domain level (Bacteria), phylum level (Gammaproteobacteria), and at the 
family level (Enterobacteriaceae and Lactobacillus) were used. Primers included F: 
(ACTCCTACGGGAGGCAGCAGT) and R: (ATTACCGCGGCTGCTGGC) for domain-level 
analyses, F: (TCGTCAGCTCGTGTYGTGA) and R: (CGTAAGGGCCATGATG) for 
Gammaproteobacteria, and F: (GTGCCAGCMGCCGCGGTAA) and R: 
(GCCTCAAGGGCACAACCTCCAAG) for Enterobacteriaceae and F: 
(AGCAGTAGGGAATCTTCCA) and R: (CACCGCTACACATGGAG) for Lactobacillus 
(Thermo Fisher Scientific). 10-fold dilution standards were made from purified genomic DNA 
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from reference bacteria. Reactions were run at 95°C for 3’, followed by 40 cycles of 95°C for 
15” and a 63°C (Bacteria) or 67°C (Enterobacteriaceae) for 60” using a Step One Plus Real-Time 
PCR instrument (Applied Biosystems, Foster City, CA). 
Enzyme-Linked Immunosorbent Assay.  
Mice in all four groups were sacrificed three hours after the last gavage on day 7.  Large 
intestines were harvested and homogenized. The homogenates were analyzed for IL-22 
(eBioscience) and IL-17 (R&D Systems) using their respective ELISAs per the manufacturer’s 
instructions. The cytokine levels were expressed per milligram of total protein in the 
homogenates. 
Western.  
Following sacrifice after the last gavage on day 7, large intestines were homogenized.  
Homogenates were analyzed by SDS-PAGE and were transferred to either PVDF or 
nitrocellulose membranes. The membrane was blocked for 1 hour at room temperature with 5% 
BSA in TBS-T (0.05% Tween 20 in TBS). Following this, the membrane was incubated with a 
desired antibody (e.g., anti-STAT3, Cell Signaling Technology, anti-pSTAT3, Cell Signaling 
Technology, or anti-β-actin, Cell Signaling Technology) overnight at 4°C. Membranes were 
washed with TBS-T and incubated with secondary antibody conjugated with horseradish 
peroxidase for one hour. After the incubation in the secondary antibody, the membrane was 
washed five times for five minutes in TBS-T and one time for 10 minutes in TBS. Following the 
final wash the membranes were probed using Western Lightning™ Chemiluminescence Reagent 
Plus (PerkinElmer, Norwalk, CT). The membrane was visualized using a ChemiDoc System. 
Statistics.  
Comparisons within groups were analyzed using a two-Way ANOVA with a Tukey post-
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hoc test. Analysis was done using GraphPad Prism software. A confidence level of p < 0.05 was 
considered statistically significant. Significance is represented as follows: * p < 0.05, ** p < 
0.01, *** p < 0.001, **** p < 0.0001. 
Results 
 
 We first examined the effect of rIL-22 treatment on the two most common assessments of 
UC severity in mouse models – weight loss and colon length.  Figure 21A shows that DSS 
Ethanol treated mice repeatedly loose significantly more weight than DSS Vehicle mice, ~12.5% 
vs. ~6%, respectively.  However, the average weight loss in DSS Ethanol mice treated with rIL-
22 on days 5 and 6 was back to that of DSS Vehicle on day 7, ~6%.  As we’ve previously 
observed, Figure 21B shows that our binge alcohol paradigm after DSS-induced colitis 
significantly decreases colon length.  Treatment with rIL-22 in the DSS Ethanol +rIL-22 reverted 
colonic shortening back to levels of DSS Vehicle treated mice.    
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Figure 21. rIL-22 Treatment Prevented the Alcohol Induced Increase in Weight Loss and 
Colonic Shortening Following DSS-Induced Colitis. A. Percent weight change of animals was 
determined by the following equation: % weight change = (weight at day X-weight at day 
0/weight at day 0)*100. Values are mean ± SEM 6-12 animals per group.  By ANOVA on day 7 
with Tukey post-hoc *p<0.05 WT DSS Ethanol vs. WT DSS Vehicle; **p<0.01 WT DSS 
Ethanol + rIL-22 vs. WT DSS Ethanol + PBS. B. Colon length measured in centimeters (cm) on 
day 7. Values are means ± SEM, n=6-12 animals/group. *p<0.05 WT DSS Ethanol vs. WT DSS 
Vehicle; ***p<0.01 WT DSS Ethanol + rIL-22  vs. WT DSS Ethanol + PBS by ANOVA with 
Tukey Post-hoc.  
 
 Alterations of the large intestine microbiome are commonly associated with severity of 
UC pathogenicity.  Our lab has previously observed increases in Enterobacteriaceae, a 
potentially pathogenic family of bacteria, and decreases in Lactobacillus, a potentially beneficial 
family of bacteria, following DSS-induced colitis and alcohol. Therefore, we performed 
quantitative real-time PCR on 16S ribosomal RNA of Enterobacteriaceae and Lactobacillus on 
large intestine luminal content to determine whether treatment with rIL-22 could restore the 
microbial changes we observed in our model of binge alcohol and colitis.  Copies of Total 
Bacteria within the large intestine luminal content via qRT-PCR analysis were used for 
normalization. Animals were housed in the same room and fed the same diet for a minimum of 
two weeks before beginning experiments to assimilate microbial exposure. 
 In line with our previous results, DSS Ethanol treated mice have a large increase in 
Enterobacteriaceae (~4 fold) on day 7 compared to DSS Vehicle treated mice.  rIL-22 treatment 
not only reduced the Enterobacteriaceae copy number in the DSS Vehicle group, but also 
dramatically reduced Entero copy number in the DSS Ethanol group back to that of DSS Vehicle 
+ PBS, Figure 22A.  Copy number of Lactobacillus was decreased ~1 fold in DSS Ethanol mice 
compared to DSS Vehicle.  Treatment with rIL-22 was able to partially restore Lactobacillus 
copy number, but it was not back to the level of DSS Vehicle, Figure 22B.   
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Figure 22. rIL-22 Prevents Overgrowth of Gram-negative Enterobacteriaceae and Partially 
Restores Lactobacillus Copy Numbers Following Alcohol and Colitis. Real-time PCR 16S 
rRNA sequencing of large intestine luminal content with primers specific for A. 
Enterobacteriaceae, B. Lactobacillus, and A-B. Total Bacteria.  
 
 IL-22 signals by binding to its cognate receptor on intestinal epithelial cells, which 
activates the transcription factor STAT3.  To determine if IL-22 was mediating acute protective 
effects through STAT3, we administered IL-22 in STAT3 deficient mice and assessed weight 
loss, colonic shortening, and microbial dysbiosis.  Figure 23A and B show that IL-22 
administration in STAT3 -/- mice did not rescue weight loss or colonic shortening in DSS 
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Ethanol mice. 
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Figure 23. rIL-22 Treatment in STAT3-/- Could Not Prevent Alcohol Induced Increases in 
Weight Loss and Colonic Shortening Following DSS-Induced Colitis. A. Percent weight 
change of animals was determined by the following equation: % weight change = (weight at day 
X-weight at day 0/weight at day 0)*100. Values are mean ± SEM 6-12 animals per group.  By 
ANOVA on day 7 with Tukey post-hoc *p<0.05 STAT3 -/- DSS Ethanol +rIL-22 against all 
other groups.  B. Colon length measured in centimeters (cm) on day 7. Values are means ± SEM, 
n=6-12 animals/group.  
 
qRT-PCR of Enterobacteriaceae in STAT3 -/- mice shows that DSS Ethanol + PBS 
group of mice had dramatic increases in Enterobacteriaceae copy number compared to DSS 
Vehicle + PBS.  Interestingly, unlike in wildtype mice where IL-22 treatment was able to 
mitigate the large increases in Enterobacteriaceae, STAT3-/- DSS Ethanol mice treated with IL-
22 mice had even further increases in Enterobacteriaceae, Figure 24A.   
B. 
S T
A T
3  
- /-
 D
S S
 V
e h
ic
le
 +
 P
B S
S T
A T
3  
- /-
 D
S S
 E
th
a n
o l
 +
 P
B S
S T
A T
3  
- /-
 D
S S
 V
e h
ic
le
 +
 r I
L -
2 2
S T
A T
3  
- /-
 D
S S
 E
th
a n
o l
 +
 r I
L -
2 2
0
2
4
6
8
C
o
lo
n
 L
e
n
g
th
 (
c
m
)
69 
 
Figure 24. rIL-22 Prevents Overgrowth of Gram-negative Enterobacteriaceae and Partially 
Restores Lactobacillus Copy Number Through STAT3 Following Alcohol and Colitis. Real-
time PCR 16S rRNA sequencing of large intestine luminal content with primers specific for A. 
Enterobacteriaceae, B. Lactobacillus, and A-B. Total Bacteria.  
 
Taken together, these data support our hypothesis that IL-22 promotes intestine health 
and mitigates microbial dysbiosis following binge alcohol and DSS colitis, however these IL-22 
protective effects are dependent on STAT3 signaling.  Although we observed beneficial effects 
with administration of recombinant IL-22, treatment of UC patients with a recombinant protein is 
not the most viable option due to potentially detrimental systemic side effects.   
Probiotics are widely used and are available without a prescription.  Therefore, we 
wanted to understand whether treatment with a bacteria commonly found in over the counter 
probiotics, Lactobacillus delbrueckii, could mediate protective effects in the context of binge 
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alcohol and UC.  For these studies, we utilized our established model of 2% DSS in the drinking 
water of mice followed by a three-day binge alcohol paradigm or water.  However, on day 4 
mice were further subdivided into mice receiving 1X1011 CFUs of Lactobacillus delbrueckii on 
the evenings of day 4, 5, and 6.  This resulted in four overall experimental groups – DSS 
Vehicle, DSS Ethanol, DSS Vehicle +Lacto, and DSS Ethanol +Lacto.  
 In line with ours and other’s previous reports, mice in both the DSS Vehicle and DSS 
Ethanol groups began losing weight on day 5 as is expected with the UC disease being induced 
by DSS.  Furthermore, mice in the DSS Ethanol group lost significantly more weight compared 
to DSS alone, ~8% vs. ~4.5%, respectively; a consistent finding in our lab with the addition of 
ethanol to DSS treated mice. Interestingly, treatment with Lactobacillus delbrueckii not only 
mitigated weight loss (~2% body weight loss in DSS Vehicle + Lacto group vs. ~4.5% loss in 
DSS Vehicle mice), it also attenuated weight loss in the DSS Ethanol treated mice, which is 
demonstrated by the DSS Ethanol + Lacto group’s average weight loss returning to levels near 
that of DSS Vehicle on day 7 (Figure 25A).  Colon length was also normalized with 
Lactobacillus delbrueckii treatment.  Figure 25B shows that mice in the DSS Ethanol treatment 
group again experienced significant increases in colonic shortening compared to DSS Vehicle 
mice.   However, when DSS Ethanol mice were given Lacto, DSS Ethanol + Lacto group, their 
colon length was back to that of DSS Vehicle.  
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Figure 25. Treatment with Lactobacillus delbrueckii Attenuated the Alcohol Induced 
Increases in Weight Loss and Colonic Shortening Following DSS Colitis. A. Percent weight 
change of animals was determined by the following equation: % weight change = (weight at day 
X-weight at day 0/weight at day 0)*100. Values are mean ± SEM n = 6-8 animals per group. 
*p<0.05 DSS Ethanol vs. DSS Vehicle by ANOVA on day 7 with Tukey post-hoc. B. Colon 
length measured in centimeters (cm) on day 7. Values are means ± SEM, n=6-8 animals/group. 
*p<0.05 DSS Ethanol compared to DSS Vehicle; ***p<0.01 DSS Vehicle + Lacto compared to 
DSS Ethanol; ****p<0.001 DSS Ethanol + Lacto compared to DSS Ethanol by ANOVA with 
Tukey Post-hoc. 
 
Secondly, we sought to determine whether treatment with the probiotic, Lactobacillus 
delbrueckii, could also normalize aspects of the dysbiosis our lab has observed following DSS-
induced colitis and binge alcohol consumption.  We again performed quantitative real-time PCR 
on 16S ribosomal RNA of Gammaproteobacteria, Enterobacteriaceae, and Lactobacillus on 
large intestine lumenal content with copies of Total Bacteria used for normalization.  Our results 
showed a large 10 – fold increase in Enterobacteriaceae in DSS Ethanol mice compared to DSS 
Vehicle. However, as can be seen in Figure 26A, the large increase in Enterobacteriaceae seen 
in the DSS Ethanol group was impressively back to the levels of DSS Vehicle when DSS 
Ethanol mice were treated with Lacto. This accompanied a slight increase (0.5 – fold) of 
Gammaproteobacteria, the phylum in which Enterobacteriaceae belongs, in DSS Ethanol treated 
mice compared to DSS Vehicle, which also decreased back to levels lower than DSS Vehicle 
following treatment with Lacto, Figure 26B.  Figure 26C shows that copies of Lactobacillus 
were decreased in DSS Ethanol compared to DSS Vehicle. Interestingly, when both groups were 
treated with Lacto, copies of Lactobacillus drastically increased in DSS Vehicle mice, but not 
DSS Ethanol.  While the mechanism underlying this observation remains to be established, our 
data supports the hypothesis that treatment with Lactobacillus delbrueckii is able to modulate the 
alcohol-induced exacerbation of UC flare we see in our model of DSS-colitis and binge alcohol.  
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Figure 26. Lactobacillus delbrueckii Prevents Overgrowth of Gram-negative 
Enterobacteriaceae. Real-time PCR 16S rRNA sequencing of large intestine luminal content 
with primers specific for A. Enterobacteriaceae B. Gammaproteobacteria, C. Lactobacillus, and 
A-C. Total Bacteria.  
 
Next, we wanted to elucidate the potential mechanism by which Lactobacillus 
delbrueckii provided these protective effects from UC flare and binge alcohol. As treatment with 
Lactobacillus delbrueckii has been shown to increase levels of IL-22, we assessed levels of large 
intestine IL-22.  Consistent with our previous findings, levels of IL-22 in DSS Ethanol mice 
compared to DSS Vehicle were significantly decreased.  In the DSS Ethanol + Lacto group, 
Lacto treatment was able to increase levels of IL-22, though not back to levels of DSS Vehicle. 
Figure 27A. As the cytokines IL-22 and IL-17 are so closely related with IL-22 regarded as anti-
inflammatory and IL-17 as pro-inflammatory, we also measured levels of colonic IL-17. 
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Treatment with Lacto in the DSS Ethanol group was able to reduce large intestine levels of IL-17 
compared to DSS Vehicle, but not compared to DSS Ethanol, Figure 27B.  
Figure 27. Lactobacillus delbrueckii Treatment Trended Towards an Increase in Large 
Intestine Levels of IL-22, but Did Not Decrease Levels of IL-17. A. Levels of total large 
intestine IL-22 quantified by ELISA. Values are mean ± SEM 6-8 animals per group. *p<0.05 
DSS Ethanol vs. DSS Vehicle by ANOVA with Tukey post-hoc. *p<0.05 DSS Ethanol vs. DSS 
Ethanol + Lacto by student’s t-test. B. Levels of total large intestine IL-17 quantified by ELISA. 
Values are mean ± SEM 6-8 animals per group. *p<0.05 DSS Ethanol + Lacto vs. DSS Vehicle 
by ANOVA with Tukey post-hoc.  
  
One way IL-22 elicits its protective effects is through the phosphorylation and thus, 
activation of the transcription factor, STAT3.  Phosphorylation of STAT3 allows for 
upregulation of genes involved in the production of AMPs and anti-inflammatory cytokines.  
Therefore, we measured levels of both STAT3 and pSTAT3 in large intestine homogenates 
following treatment with Lactobacillus delbrueckii.  Figure 28 shows that large intestine levels 
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of pSTAT3 in DSS Ethanol mice are decreased compared to that of DSS Vehicle.  Interestingly, 
when DSS Ethanol mice were treated with Lacto, levels of pSTAT3 increased back to that of 
DSS Vehicle.   
 
Figure 28. Treatment with Lactobacillus delbrueckii Attenuates Decreased Levels of 
pSTAT3 in DSS Ethanol Mice. Protein isolated from total large intestine tissue was probed for 
STAT3 and pSTAT3 (Y705) by Western blot. Densiometric analysis was performed to express 
the ratio of pSTAT3/β-actin. 
 
 Finally, we wanted to answer the question of whether the beneficial effects we observed 
following treatment with Lactobacillus delbrueckii was due to the bacteria itself or a potential 
factor released by the bacteria.  As can be seen in Figure 29A and B, in order to reduce weight 
loss and colonic shortening back to the level of DSS Vehicle treated mice, DSS Ethanol treated 
mice must receive whole Lacto bacteria.  Treatment with Lacto supernatant alone, DSS Ethanol 
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+ Lacto Sup group, resulted in weight loss and colonic shortening comparable to that of DSS 
Ethanol mice that were not treated with Lacto.  
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Figure 29. Lactobacillus delbrueckii Bacteria are Required to Attenuate the Alcohol 
Induced Increases in Weight Loss and Colonic Shortening Following DSS Colitis. A. 
Percent weight change of animals was determined by the following equation: % weight change = 
(weight at day X-weight at day 0/weight at day 0)*100. Values are mean ± SEM n = 5 animals 
per group. **p<0.01 DSS Ethanol vs. DSS Vehicle by; **p<0.01 DSS Ethanol + Lacto Sup. vs 
DSS Vehicle by ANOVA on day 7 with Tukey post-hoc. B. Colon length measured in 
centimeters (cm) on day 7. Values are means ± SEM, n=5 animals/group. *p<0.05 DSS Ethanol 
compared to DSS Vehicle; **p<0.01 DSS Ethanol + Lacto Sup compared to DSS Vehicle; ns= 
not significant DSS Ethanol + Lacto Bacteria vs DSS Vehicle by ANOVA with Tukey Post-hoc. 
 
Summary 
Here, we demonstrated that the alcohol induced exacerbation of UC symptoms including 
increased weight loss, colonic shortening, and large intestine Enterobacteriaceae copy number 
can be attenuated by exogenous administration of recombinant IL-22. Our findings further 
demonstrate that IL-22-mediated protection requires STAT3 signaling in intestinal epithelial 
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cells, as STAT3-/- knockout mice did not benefit from IL-22 treatment following DSS-induced 
colitis and alcohol.  
Treatment with the probiotic, Lactobacillus delbrueckii, was also able to mediate 
protection against exacerbated UC symptoms of weight loss and colonic shortening following 
binge alcohol consumption. Furthermore, Lacto treatment was able to reduce the large increases 
in the pathogenic bacteria, Enterobacteriaceae, that we see following DSS-colitis and binge 
alcohol back to that of non-alcohol treated mice.  As treatment with Lacto was also able to 
increase levels of IL-22, which resulted in increased levels of pSTAT3, our results highlight a 
potential mechanism by which this probiotic elicited protective effects against alcohol-induced 
worsening of UC flare.  Therefore, Lactobacillus delbrueckii treatment could potentially be a 
therapeutic option for UC patients experiencing symptom exacerbation and/or prolonged flare 
due to alcohol use by tipping the scales into a period of remission.  
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CHAPTER SIX 
 
BINGE ALCOHOL FOLLOWING DSS-INDUCED COLITIS INCREASES SUSCEPTIBLITY 
TO INFECTION  
 
Abstract 
 
Ulcerative colitis (UC) is a life-long disease with periods of remission and disease flares 
characterized by abdominal pain, increased weight loss, intestinal inflammation, and rectal 
bleeding. In addition to treatment with medication, UC patients are commonly warned against 
alcohol use.  One study found IBD patients self-reported a worsening of GI symptoms following 
alcohol consumption. With our mouse model of binge alcohol exposure following induced 
colitis, we found increased weight loss, colon shortening, and large intestine inflammation in 
mice exposed to alcohol. We sought to elucidate whether alcohol consumption not only 
perpetuated an UC flare, but also whether alcohol increased susceptibility to the enteropathogen 
C. rodentium. Male mice received DSS for 5 days. On days 5, 6, and 7 mice were gavaged with 
alcohol (~3g/kg) or water. Three hours after the last gavage on day 7, mice were orally 
administered C. rodentium at 1 X105 CFUs. Body weight and mortality were monitored. On day 
11, mice were euthanized and colons harvested to measure length, inflammatory markers such as 
IL-18, IL-1β, IL-6, TNFα, and KC proteins levels via ELISA, and the tight junction protein 
expression. Colon sections were stained by H&E and alcian blue. C. rodentium infection in mice 
following DSS and alcohol treatment resulted in increased weight loss compared to those 
receiving DSS alone and C. rodentium. We observed a 50% reduction in survival in DSS alcohol 
treated mice following C. rodentium infection compared to 100% survival with DSS and C. 
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rodentium. This accompanied a significant decrease in colon length in DSS alcohol treated mice 
following C. rodentium infection compared to DSS and C. rodentium. Mice infected with C. 
rodentium following DSS and alcohol had significant decreases in claudin 8 and occludin 
compared to all groups.  H&E staining revealed prominent colonic damage and inflammatory 
infiltrate in DSS alcohol plus C. rodentium infected mice. Histopathology was scored in a 
blinded fashion, and we found significant increases in histopathology scores in DSS alcohol and 
C. rodentium treated mice compared to DSS and C. rodentium. In the DSS ethanol and C. 
rodentium group, 8/12 mice showed a decrease in the mucus layer along with a decrease in 
goblet cells. Mice in the DSS Ethanol + C. rod group experienced significantly increased levels 
of IL-18 and IL-1β in colonic homogenates compared to DSS Vehicle + C. rod.  IL-6 was 
increased in both the DSS Ethanol + C. rod and DSS Vehicle + C. rod compared to mice treated 
with DSS alone. Interestingly, levels of TNFα and KC were not further increased following C. 
rod infection after DSS Ethanol treatment.  Utilizing luciferase expressing C. rod, we were also 
able to show that mice infected with C. rodentium following DSS and alcohol had increased 
colonization by C. rodentium on day 11 compared to DSS Vehicle + C. rod  treated mice.  Along 
with our previous findings, these data suggest alcohol increases susceptibility to enteropathogens 
in mice with DSS-induced colitis. 
Introduction 
Under normal homeostatic conditions, the large intestine employs a whole host of 
defenses against invading pathogenic bacteria.  Firstly, the mucus layer serves to protect barrier 
integrity by limiting the amount of interaction between luminal contents and intestinal epithelial 
cells.  Irregular mucin profiles of the most prevalent mucin in the colon, mucin-2, have been 
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demonstrated in disease states of IBD.  Furthermore, decreased mucin-2 expression correlated 
with increased ability of pathogens to cross the intestinal barrier. 
Secondly, proper intestinal function requires the formation and maintenance of a selective 
barrier formed by tight junction proteins of intestinal epithelial cells, which retain commensal 
microbes to the lumen while allowing passage of critical nutrients.  Literature from other 
laboratories has shown significant disruptions in claudin-2, claudin-4, and occludin expression in 
colons of patients with UC.  
Thirdly, proper levels of inflammation are the body’s response to harmful stimuli, such as 
invading pathogens.  Pattern-recognition receptors (PRRs) on macrophages will recognize 
antigens on microbes which initiates a coordinated inflammatory cascade involving the release of 
pro-inflammatory cytokines such as IL-1β, IL-6, and TNFα.  Activated macrophages will also 
release pro-inflammatory chemokines, such as KC, which signal the recruitment of neutrophils, 
NK cells, and other pro-inflammatory lymphocytes.  In a healthy individual, this inflammatory 
cascade is coordinated in such a way to maintain tolerance to the body’s commensal microbes, 
but eliminate pathogenic bacteria.  In the context of UC, tolerance towards the resident 
microbiome is broken, resulting in an over activation of inflammatory pathways.  Consequently, 
these consistenly high levels of intestinal inflammation produce severe tissue damage, thus 
compromising the integrity of the intestinal barrier leaving it susceptible to invading pathogens.  
Therefore, in addition to the many other co-morbidities associated with UC, patients 
experience higher rates of intestinal infections.  Further compounding the problem, treatment of 
UC-associated intestinal inflammation with the above listed anti-inflammatory treatments results 
in overall immunosuppression, potentially allowing the invasion of pathogenic bacteria that 
would have normally been defended against.  Furthermore, changes in bacterial populations from 
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broad-spectrum antibiotic treatment could open specific niches more favorable to invading 
pathogens, which then gives rise to the increased susceptibility to bacterial infections seen in 
IBD/UC patients.  Thus by simply treating the symptoms of UC (inflammation and dysbiosis), 
we could actually be feeding the cycle of remission to flare to remission.  These opposing ideas 
make critical the need for further research into what could be leading to UC patients 
experiencing higher rates of infection.  Knowing that alcohol alone can increase propensity to 
infection, we sought to understand whether alcohol consumption in a model of UC plays a role in 
increased rates of infection seen in UC patients. 
Our results demonstrate that mice receiving C. rodentium following alcohol and DSS-
induced colitis had decreased survival and increased weight loss, colon shortening, 
histopathology scores, a decreased colonic mucosal layer and goblet cell number, decreased tight 
junction protein expression, increased inflammation, and increased colonization by C. rodentium. 
These findings highlight alcohol’s ability to potentiate susceptibility to infection in UC, and 
show the dramatic increase in UC symptoms following a bacterial infection when intestinal 
barrier defenses are further compromised by the consumption of alcohol.  
Materials and Methods 
Induction of DSS Colitis and Binge Alcohol.  
Male 8-9 week old (~23-25g body weight) C57BL/6 mice were obtained from Charles 
River Laboratories (Wilmington, MA). Briefly, as can be seen in Figure 30, mice were randomly 
separated into four experimental groups: Sham Vehicle, Sham Ethanol, DSS Vehicle, and DSS 
Ethanol. DSS treated mice received 2% (wt/vol) DSS (40,000 kDa; MP Biomedicals), ad 
libitum, in their drinking water for five days. Mice in the Sham group received water only for 5 
days acting as a control. On day 5, DSS was discontinued and replaced with normal drinking 
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water in both the DSS and Sham/control groups. On day 5, mice in both the DSS and 
Sham/control group were further subdivided into two subgroups: mice gavaged with alcohol 
(~3g/kg) or mice gavaged with water on days 5, 6, and 7 to mimic a binge alcohol abuse pattern. 
The amount of DSS water drank per animal was recorded and no differences in intake between 
groups were observed. Mice were weighed every day for the determination of percent weight 
change. This was calculated as: % weight change = (weight at day X- weight at day 0/weight at 
day 0) X 100. Animals were monitored clinically for rectal bleeding, diarrhea, and general signs 
of morbidity, including hunched posture and failure to groom. 
Citrobacter rodentium (C. rod) Infection.  
Mice were subjected to the DSS-induced colitis and binge alcohol paradigm as described 
above. However, after the last gavage on day 7, mice were further divided into two subgroups: 
mice gavaged with 1 X 105 CFUs of C. rod suspended in 300 mL of PBS or 300 mL of PBS 
alone. This resulted in four experimental groups: DSS Vehicle, DSS Ethanol, DSS Vehicle + C. 
rod, and DSS Ethanol + C. rod.  
For C. rod colonization experiments, a bioluminescent strain of C. rodentium was used.  
This strain was gifted to us by Dr. Sara Jones of Loyola University Chicago who had the 
permission of Dr. Gad Frankel (Imperial College London), whose lab created this strain. In short, 
the luxCDABE operon was introduced into the C. rodentium bacterial strain. The luxCDABE 
operon encodes for luciferase and the enzymes required for aldehyde substrate recycling. 
Bioluminescent colonies were plated to purity as single colonies and lux+ phenotype confirmed 
by luminometry prior to storage under glycerol at −80°C.  Mice were separated into two groups: 
, DSS Vehicle + C. rod lux+, and DSS Ethanol + C. rod lux+, both of which received 1 X 105 
CFUs of C. rod lux+ suspended in 300 mL of PBS three hours post the last gavage of either 
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alcohol or water on day 7.  On day 11, mice were gavaged with 2mg/200uL of the luciferase 
substrate, Vivoglo luciferin (Promega).  Mice were euthanized  2 hours post luciferin gavage and 
large intestines were harvested to directly assess colonization utilizing an IVIS in vivo imaging 
system (available in Loyola’s Imaging core), which captures images of photon emission from the 
bioluminescent C. rod. 
The experiments described here were carried out in adherence with the National Institutes 
of Health (NIH) Guidelines for the Care and Use of Laboratory Animals and are approved by the 
Institutional Animal Care and Use Committee, Loyola University Chicago Health Sciences 
Division, Maywood IL. 
Tissue Staining.  
For hematoxylin and eosin (H&E) staining, 2cm of colon tissue closest to the rectum was 
taken from each mouse and saved in 10% formalin. Tissue was fixed with 10% phosphate 
buffered formalin, paraffin embedded, sectioned at 5 μm, and stained with hematoxylin and 
eosin or alcian blue, which stains mucin, by AML laboratories (Saint Augustine, Florida). 
Images were taken on an Olympus BX43 Microscope using an Olympus DP26 camera.  
Histopathology Scoring.  
H&E stained sections were analyzed and scored in a blinded manner by Dr. Xianzhong 
Ding. Dr. Ding is an Associate Professor of Pathology at Loyola University Chicago and 
member of my Dissertation Committee. Scoring was based on a modified 0-4 point scale 
examining exudate, epithelial damage, polymorphonuclear leukocyte invasion, and submucosal 
edema20. The values from each of the 4 categories were added to produce a combined 
histopathology score for each animal. 
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Colon Length.  
Immediately following euthanasia, colons were excised and length measured.  
Real-time PCR Gene Analysis.  
Anti-microbial peptide transcript levels were measured using TaqMan Gene Expression 
Assay. Briefly, RNA was isolated from intestinal homegenates using a Qigaen RNEasy Kit per 
the manufacturer’s instructions (Qiagen, Hilden, Germany). Reverse transcription was performed 
using a High Capacity Reverse Transcription Kit (Applied Biosystems), and real-time PCR were 
performed per manufacturer’s instructions. Primers for Claudin 2, Claudin 4, Claudin 8, 
Occludin, and GAPDH were obtained from Applied Biosystems. 
Enzyme-Linked Immunosorbent Assay.  
Mice in all four groups were sacrificed on day 11, as seen in Figure 30. Large intestines 
were harvested and homogenized. The homogenates were analyzed for IL-18 (eBioscience), IL-
1β (R&D Systems), IL-6 (R&D Systems), TNFα (eBioscience), and KC (BD Biosciences) using 
their respective ELISAs per the manufacturer’s instructions. The cytokine levels were expressed 
per milligram of total protein in the homogenates. 
Statistics.  
Comparisons within groups were analyzed using a one-Way ANOVA with a Tukey post-
hoc test. Analysis was done using GraphPad Prism software. A confidence level of p < 0.05 was 
considered statistically significant. Significance is represented throughout the manuscript as 
follows: * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001.  
Results 
UC patients are at higher risk of developing bacterial infections28,29. To understand 
whether consumption of alcohol not only impacts UC patient’s increased susceptibility to 
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infection but also increases severity of symptoms related to bacterial infection, we utilized our 
model of DSS-induced colitis and binge alcohol, as described above, along with a single 
inoculation of C. rod, a well-known Gram negative enteropathogen associated with colonic 
infection, at 1 X 105 CFUs three hours after the last gavage on day 7 (Figure 30).  
 
Figure 30. Murine Model of DSS-Induced Colitis, Ethanol, and C. rodentium Infection. A 
2% DSS concentration was administered ad libitum in drinking water for 5 days to mimic 
symptoms of UC. On day 5, DSS was discontinued to allow entrance into UC remission. A binge 
alcohol paradigm was employed where mice were gavaged with alcohol or water on days 5, 6, 
and 7. Mice were further subdivided and were gavaged with either 1 X 105 CFUs C. rodentium 
or water 3 hours post last gavage on day 7. Mice were euthanized on day 11. 
 
As can be seen in Figure 31, the percent survival of DSS Ethanol treated mice following 
C. rod infection fell to 50% by day 11 compared to 100% survival in the DSS Vehicle group 
with C. rod infection. Interestingly, DSS Ethanol mice with no C. rod infection also experienced 
a 20% reduction in survival compared to the 100% survival in the DSS Vehicle group with and 
without C. rod infection. 
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Figure 31. Ethanol Decreased % Survival Following C. rodentium Infection. n=7-8 
animals/group. 
 
Weight loss and gain was also monitored as described previously by percent change from 
day 0 up till day 11 as only 50% of the mice in the DSS Ethanol + C. rod infection group 
survived till day 11. By day 11 following C. rod infection, mice in the DSS Ethanol group 
experienced a ~27% decrease from their original body weight compared to ~22% in the DSS 
Vehicle group (Figure 32A) giving evidence to our hypothesis of alcohol not only increasing 
susceptibility to infection with UC, but also increasing severity of symptoms associated with UC 
and infection. Increased weight loss accompanied increases in colonic shortening in the DSS 
Ethanol + C. rod group compared to mice in the DSS Vehicle + C. rod group, Figure 32B. 
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Figure 32. Alcohol Consumption Increases Weight Loss and Colonic Shortening Following 
C. rodentium Infection in DSS-Induced Colitis.  A. Alcohol consumption increases weight loss 
following C. rodentium infection in DSS-induced colitis. Values are calculated as average % 
weight change, *p<0.05 DSS Vehicle + C. rod compared to DSS Vehicle; **p<0.01 DSS 
Ethanol + C. rod compared to DSS Vehicle by Two-way ANOVA, n=7-8 animals/group. B. 
Increased colonic shortening with C. rodentium infection after alcohol consumption and DSS-
induced colitis. Values are means ± SEM, n=7-8 animals/group. *p<0.05 DSS Ethanol compared 
to DSS Vehicle; ****p<0.0001 DSS Ethanol + C. rod compared to DSS Vehicle and DSS 
Vehicle + C. rod ANOVA. 
 
Again, to understand differences in histopathology following infection with C. rod, 
sections of colon were taken closest to the rectum, stained via H&E, blinded, and scored by a 
pathologist. Figure 33A shows gross differences in large intestine morphology after DSS 
Ethanol + C. rod treatment compared to all other groups. As in Figure 9B, inflammatory 
infiltrate and epithelial damage were assessed and were severely increased in the DSS Ethanol + 
C. rod mice compared to that of the DSS Vehicle + C. rod group. The combined histopathology 
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scores in DSS Ethanol + C. rod treated mice were significantly increased compared to mice in 
the DSS Vehicle + C. rod group, Figure 33B. 
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Figure 33. Increased Colonic Damage, Inflammatory Infiltrate, and Histopathology Scores 
with C. rodentium Infection After Alcohol Consumption and DSS-Induced Colitis. A. 
Increased colonic damage and inflammatory infiltrate with C. rodentium infection after alcohol 
consumption and DSS-induced colitis. Representative H&E images, n=6-12 animals/group. B. 
Combined Histopathology Score following blinded histological scoring as described in detail in 
Methods section above. Values are mean ± SEM, n=6-12 animals/group. **p<0.01 DSS Ethanol 
+ C. rod compared to DSS Vehicle; *p<0.05 DSS Ethanol + C. rod compared to DSS Vehicle + 
C. rod and DSS Ethanol by ANOVA. 
 
To further assess colonic barrier breakdown following C. rod infection, we performed an 
Alcian blue stain, which stains the glycoproteins found in the mucosal layer lining intestinal 
epithelial cells and in large intestine goblet cells.  Eight out of the twelve mice in the DSS 
Ethanol + C. rod group showed a decrease in the mucus layer along with a decrease in goblet 
cells as can be seen in representative images in Figure 34. 
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Figure 34. Decreased Large Intestine Mucosal Lining and Goblet Cell Number with C. 
rodentium Infection After Alcohol Consumption and DSS-Induced Colitis. Representative 
Alcian blue images, n=6-12 animals/group.  
 
Proper intestinal barrier function is dependent on the formation and integrity of tight 
junction protein complexes adhering adjacent intestinal epithelial cells.  Figure 35C and 35D 
show that C. rod infection results in a significant decrease in expression of both Claudin 8 and 
Occludin in the large intestine of DSS Ethanol + C. rod mice, respectively.  Expression of 
Claudin 2 (Figure 35A) and Claudin 4 (Figure 35B) were not significantly altered in the DSS 
Ethanol treated mice following infection with the colonic pathogen, C. rodentium.  
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Figure 35. Decreased Colonic Tight Junction Expression Following C. rodentium Infection 
with Alcohol Consumption and DSS-Induced Colitis. Values are mean ± SEM, n=6-12 
animals/group. 
 
 
As we did previously, seen in Figure 11, we assessed colonic inflammation under the 
hypothesis that C. rod infection would further increase inflammation in mice receiving DSS 
Ethanol treatment, which could perpetuate increased colonization of C. rod. We found that mice 
in the DSS Ethanol + C. rod group had increased levels of IL-18 (Figure 36A) and IL-1β 
(Figure 36B) compared to DSS Vehicle + C. rod. Furthermore, the pro-inflammatory cytokine 
IL-6 was increased in both the DSS Ethanol + C. rod and DSS Vehicle + C. rod compared to 
mice treated with DSS alone (Figure 36C). However, both TNFα and KC were not further 
increased following C. rod infection after DSS Ethanol treatment (Figure 36D and 36E). 
94 
 
 
 
Figure 36. C. rodentium Further Increases Colonic Inflammation After DSS-Induced 
Colitis and Ethanol Treatment. Colons were harvested, homogenized, and processed on day 11 
for the analysis of inflammatory mediators using respective ELISAs. A. IL-18 *p<0.05 DSS 
Ethanol + C. rod compared to DSS Vehicle + C. rod and DSS Vehicle by ANOVA, B. IL-1β 
*p<0.05; **p<0.01; ***p<0.001 DSS Ethanol + C. rod compared to all other groups by 
ANOVA, C. IL-6 *p<0.05 DSS Ethanol + C. rod compared to DSS Vehicle and DSS Vehicle + 
C. rod compared to DSS Vehicle by ANOVA, TNFα, E. KC by ELISA. Values are mean ± SEM 
7-8 animals per group. 
  
Finally, to assess whether mice in the DSS Ethanol group were truly more susceptible to 
infection, we utilized a bioluminescent strain of C. rod gifted to us by Dr. Sara Jones to image C. 
rod colonization of the large intestine following DSS-induced colitis and binge alcohol.  The 
luxCDABE operon was introduced into the C. rod strain and bioluminescent colonies (lux+) 
were plated to purity and utilized for these experiments.  As can be seen in Figure 37, mice in 
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the DSS Ethanol + C. rod lux+ group have higher levels of photon emission (as seen by 
increased red and blue areas) in their intestines indicative of increased C. rod colonization 
compared to DSS Vehicle + C. rod lux+. 
 
Figure 37. Increased C. rodentium Colonization in DSS Ethanol Mice Compared to DSS 
Vehicle.  
 
Summary 
 
Research has shown that IBD patients and alcoholic patients carry an intestinal bacterial 
dysbiosis50,83. A dysbiosis is believed to provide pathogens an opportunity to colonize and 
proliferate158 . Indeed, studies have shown IBD patients and alcoholics are at risk for increased 
infections159,160. In a retrospective analysis of patients with a documented history of alcohol use 
and IBD, our lab found that these patients had increased intestinal infections.  With our low 
inoculate of C. rodentium in our murine model of binge alcohol and DSS-induced colitis, we 
were able to mimic these patient’s results as DSS Ethanol treated mice had increased 
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susceptibility and colonization of C. rodentium.  We recognize the burden of utilizing the model 
pathogen, C. rodentium, which itself is used as a model of IBD, on top of our binge alcohol and 
DSS-induced colitis model. Yet, our adaptation of using a much lower inoculate, 1 X 105 CFUs 
vs. 1 X 1011 CFUs to induce true IBD symptoms, allowed us to shed light on the increased 
propensity for IBD patients who drink alcohol to acquire intestinal infections161. 
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CHAPTER SEVEN 
DISCUSSION 
New Contributions to the Alcohol and Ulcerative Colitis Field 
The overarching goal of this work was to expand our understanding of how binge alcohol 
drinking could potentially worsen GI symptoms of UC and to identify potential treatment 
regimens to improve lives of UC patients.  While a good amount of work has been and still is 
dedicated to elucidating a cure for UC, it is imperative that research continues in attempt to not 
only understand the triggers of flare, but also maintenance therapies to keep patients in remission 
and out of active UC flare.  A report from the U.S. Department of Health and Human Services at 
the Centers for Disease Control and Prevention stated that the peak age at which patients are 
diagnosed with IBD is between 20-401.  Interestingly, a study conducted by Naimi et al. found 
this is also the age range where an estimated 70% of binge alcohol drinking episodes occur15.  
These two independent observations highlight the need to investigate a potential correlation 
between binge alcohol drinking and UC diagnoses.  However, contrasting evidence as to whether 
drinking alcohol worsens UC symptoms in patient populations made it necessary for our lab to 
generate a mouse model of UC and binge alcohol drinking.  
The results presented here demonstrate that binge alcohol drinking can exacerbate an UC 
flare period in a mouse model of UC shown by increased weight loss, colonic shortening, 
histopathology and clinical scores, inflammation, microbial dysbiosis, failure to release a critical 
cytokine involved in entrance into remission, IL-22, and susceptibility to infection.  
Administration of recombinant IL-22 and the probiotic, Lactobacillus delbrueckii, were effective 
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in restoring these exacerbated symptoms in a STAT3-dependent fashion.  As a whole, these 
findings provide a new insight into cellular and molecular mechanisms that may contribute to 
intestine barrier disruption following an UC flare period in the presence of intoxication, and this 
may have implication in other forms of autoimmune conditions that acutely affect intestinal 
physiology. 
Generating a Murine Model of UC and Alcohol 
One limitation of UC research is that no one murine model exactly replicates UC, as UC 
pathology is so multi-factorial.  Therefore, researchers are restricted to mimicking colitis 
symptoms in murine model systems with various chemicals such as DSS, of 2,4,6-
trinitrobenzenesulfonic acid (TNBS), or oxazolone.  These chemicals damage the integrity of the 
large intestine triggering innate and adaptive inflammatory cascades and intestinal dysbiosis, 
which presents UC-like symptoms.  Whether the inflammation or the dysbiosis is the initiating 
factor in inducing the other is still unknown and a matter of debate amongst UC researchers.  Our 
laboratory choose to utilize DSS in generating our model due to its reproducibility in initiating 
UC symptoms and ease use.  Anywhere from a 1-5% concentration of DSS is used in the field of 
UC research.  Therefore, when generating our model, we first profiled 2, 3, and 4% 
concentrations in order to understand not only what works in our hands and laboratory 
environment, but also to whether DSS produced the expected UC symptoms.  The exact 
mechanism behind which DSS damages the intestinal barrier is still unknown.  However, DSS-
induced intestinal damage is likely through a combination of disturbance in the metabolism of 
phospholipids, which are major cellular constituents required for the assembly of biological 
membranes and loss of tight junction protein ZO-1, which could facilitate in increasing intestinal 
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permeability.  We found that all three concentrations of DSS we utilized, indeed, were able to 
induce UC-like symptoms in treated mice.   
The NIAAA defines binge drinking as a pattern of drinking that brings blood alcohol 
concentration (BAC) levels to 0.08 g/dL in a single dose.  For the past 15 years our lab has had a 
murine model of alcohol and burn injury, which utilizes a single dose of alcohol at ~3g/kg per 
mouse.  Therefore, we used this alcohol dose when generating our model of UC and binge 
alcohol.  We tested two binge alcohol paradigms, a one-day binge on the last day as seen in 
Figure 4 and a three-day binge as seen in Figure 6.  Our results demonstrated that a 2% DSS 
concentration followed by a three-day binge alcohol paradigm was the best experimental model 
to begin to elucidate how alcohol could be perpetuating an UC flare.  We were able to show that 
DSS Ethanol treated mice had exacerbated symptoms of UC as shown by increases in weight 
loss, colon shortening, more profound histopathology and clinical scores, and increased intestinal 
inflammation, all of which are standard assessment of UC severity in mouse models.  To our 
knowledge, this is the first time a murine model of UC and alcohol has been developed to allow 
a better understanding of how drinking alcohol could affect a patient with UC. 
However, two questions remain: 1) Whether alcohol can trigger an UC flare? and 2) 
Whether drinking alcohol predisposes one to a UC diagnosis? 
Alcohol Use as a Trigger and/or Predisposition for UC 
 The results of our work demonstrate alcohol’s ability to worsen an induced flare period 
(i.e. 5 days of DSS).  Once DSS was removed on day 5, DSS Vehicle treated mice showed signs 
of entrance into remission as seen by less severe histopathology and clinical scores, decreased 
intestinal inflammation, and increased protein levels of IL-22 compared to DSS Ethanol treated 
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mice.  We recognize the limitation in our alcohol and colitis model that a person experiencing an 
UC flare might not participate in an alcohol binge.   
 Therefore, future work will focus on inducing an UC flare with DSS in the drinking water 
for 5 days as per our model in Figure 6, but instead of an immediate binge of alcohol, mice will 
be allowed to recover for one week to model entrance into UC remission.  Then we will 
implement our three-day binge alcohol paradigm to assess whether a binge of alcohol during a 
period of UC remission can trigger an UC flare.  Preliminary data from our laboratory utilizing 
this model does indeed show that an alcohol binge can induce UC flare symptoms even during an 
UC remission period. 
 To answer the question of whether alcohol could predispose one to UC, we will utilize an 
IL-10 deficient mouse.  IL-10 is an immunoregulatory cytokine essential in the maintenance of 
intestinal homeostasis.  A wide range of immune cells secrete IL-10 such as macrophages, 
dendritic cells, and T cells, which suppresses effector functions of Th1/Th17 cells as well as NK 
cells and macrophages, thereby modulating the cellular immune response162-164.  Interestingly, a 
genetically engineered IL-10–deficient mouse has been extensively used to dissect IBD etiology. 
IL-10 knockout mice were first generated in 1993 by Kühn et al.165.  The generation was 
performed by use of targeted mutation disrupting the IL-10 gene by replacing a 500 base pair 
fragment of exon 1 with a termination codon and a neo expression cassette and by introducing a 
termination codon into exon 3 (Il10tm1Cgn, IL10−/−).  IL-10 deficiency produces discontinuous 
and transmural inflammatory lesions characterized by inflammatory cell infiltrates into the 
lamina propria and submucosa, epithelial hyperplasia, mucin depletion, crypt abscesses, ulcers, 
and thickening of the intestinal wall166,167, all of which are symptoms of human UC.  The onset 
of gut inflammation in IL-10 knockout mice occurs spontaneously after weaning168.  
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 To answer the question of whether alcohol consumption increases risk of UC diagnosis, 
we hope to utilize IL-10 knockout mice and employ a binge alcohol paradigm before UC 
spontaneously sets in.  If a binge of alcohol produced UC symptoms at an earlier time point or in 
an exacerbated passion, this would provide evidence for alcohol use directly influencing UC risk.  
Thus, future work will be dedicated in designing a binge alcohol paradigm in IL-10 knockout 
mice.  
Interleukin-22 in UC Remission 
One potential pathway that upon its activation could act in the amelioration of DSS-
induced colitis is the aryl hydrocarbon receptor (AhR) pathway. Studies have shown that 
activation of the AhR pathway not only through chemical activation via TCDD (2,3,7,8-
tetrachlorodibenzo-pdioxin) but also by specific probiotics is able to inhibit DSS-induced 
colitis132,169 . Additionally, cytokines known to be induced upon AhR activation, specifically IL-
22, are known to be upregulated during remission periods of UC98,143 . 
IL-22 remains one of the most intriguing cytokines due to its ability to elicit completely 
different responses based on the microenvironment. In the context of the intestines, the presence 
of IL-22 appears to be beneficial under most circumstances including inflammatory bowel 
disease, graft-versus-host disease, and many types of bacterial infection102,153,170-173. 
Interestingly, certain bacterial infections, such as in mouse models using T. gondii, cause IL-22 
to be pro-inflammatory174,175. While the reasons behind these differential responses of IL-22 
remain unknown, it illuminates the importance of understanding the role of IL-22 under different 
conditions. In addition, current clinical trials using Fc-fusion IL-22 administration for treatment 
of patients with graft-versus-host disease have shown promising preliminary results, indicating 
that IL-22 treatment may be efficacious in a clinical setting176. 
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The increased weight loss, colonic shortening, more profound histopathology and clinical 
scores, and increased intestinal inflammation outlined in Chapter 3 clearly demonstrate alcohol’s 
role in increasing symptoms of UC flare.  Combined with the knowledge that IL-22 is a critical 
cytokine for entrance into UC remission, we examined whether alcohol was affecting IL-22 
levels and thus perpetuating UC flare.  Our results show that mice allowed to recover for 3 days 
(DSS Vehicle group) experienced increased levels of IL-22 in large intestine homogenates.  In 
mouse models of colitis, the innate immune response in the colon includes recruited 
macrophages and neutrophils, which appear to have both pro-inflammatory and anti-
inflammatory roles in colitis177.  Specifically, aberrant control of these infiltrating neutrophils 
can result in tissue damage in the colon caused by abundant reactive oxygen species178-180. 
However, recent studies demonstrated that neutrophils can play a protective role in the host 
response in acute models of colitis by producing IL-22181,182.  Hence, we examined whether the 
spike in IL-22 levels in DSS Vehicle mice was due to infiltrating neutrophils, and conversely 
whether the diminished IL-22 response in DSS Ethanol mice was a consequence of abnormal 
control of  IL-22+ producing neutrophils.  We found that both large intestines of DSS Vehicle 
and DSS Ethanol mice had increased percentage of neutrophils.  In contrast to Zindl et al.’s 
results, these isolated neutrophils were not producing IL-22 in our model of DSS-induced colitis 
and alcohol.   
However, examination IL-22+ γδ T cells revealed that DSS Vehicle treated mice had a 
significantly increased percentage of IL-22+ γδ T cells, but this response was abolished in DSS 
Ethanol treated mice.  This balance between decreased percentages of IL-22+ neutrophils and 
simultaneous decrease in percentages of IL-22+ γδ T cell in DSS Ethanol mice gives evidence to 
how alcohol could be damaging the critical response IL-22 needed  to restore the integrity of the 
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intestine following mucosal injury and enter into UC remission.  Therefore, increasing levels of 
large intestine IL-22 in the context of binge alcohol consumption and UC could act a potential 
therapeutic target to improve lives of UC patients. 
In the intestine IL-22 can stimulate proliferation, mucous protection, and AMP secretion, 
which could drive entrance into the remission period from a UC flare99,104,109,111,182,183. The 
present study provides a mechanistic role for IL-22 mediated protection against alcohol induced 
UC flare through STAT3.  A recent report supporting this mechanism from Hanash et al. showed 
that IL-22 specifically signals through STAT3 in stem cells within the crypts of both small and 
large intestines to promote barrier regeneration in a murine model of graft versus host disease184. 
While IL-22 has been shown in other models to signal through other STATs or MAPK/ERK 
pathways185-188, we found epithelial cell STAT3 to be necessary for IL-22 mediated protection 
against alcohol-induced exacerbation of DSS-induced colitis.  
Although this is an exciting finding for the field of alcohol and colitis research, 
translating this treatment of an exogenous protein into UC patients could possible have systemic 
side-effects.  Therefore, we chose to examine probiotics as a potential therapeutic option has they 
are readily available without a prescription.   
Probiotic Intervention as a Potential Therapeutic Option 
Interestingly, we also found that treatment with the probiotic, Lactobacillus delbrueckii, 
attenuated the increased severity of UC symptoms we observe after DSS-induced colitis and 
alcohol.  Lacto treatment was able to upregulate activated colonic STAT3 following colitis and 
alcohol back to that of DSS Vehicle treated mice providing mechanistic evidence for how 
Lactobacillus delbrueckii mediates its protective effects.  
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We acknowledge that this work does not currently have any functional read outs of the 
benefits of Lacto treatment.  As activated STAT3 is known to increase intestinal epithelial cell 
proliferation, increase AMPs, and increase immunomodulatory cytokines such as IL-10, we 
expect Lacto treated mice to will also have increases in these downstream targets of activated 
STAT3.  Additionally, we expect Lacto treatment to increase percentages of IL-22+ lamina 
propria immune cells in DSS Ethanol treated mice.  Our findings in Chapter 5 not only gives 
evidence to γδ Tcells as the potential source of IL-22 in DSS Vehicle treated mice, which models 
entrance into UC remission, but also points to an inability of γδ T cells to mount the proper IL-22 
response in the presence of alcohol.  Finally, we expect FACS analysis of large intestine lamina 
propria immune cells following Lacto treatment to increase the percentage of IL-22+ γδ T cells 
in DSS Ethanol mice.  
Increased Susceptibility to Infection 
Besides symptoms associated with UC itself, UC patients have a higher propensity to 
other co-morbidities such as infection. Patients with UC are hospitalized commonly with 
worsening diarrhea, which in many instances is attributable to progression of the underlying 
IBD, but it might also be the result of infection with enteric organisms or opportunistic agents 
such as cytomegalovirus and C difficile189. Thus, prompt diagnosis and treatment of infection 
become paramount. Previous studies have reported that 5%–19% of patients admitted for 
relapsing IBD are positive for C. difficile189,190.  Rodemann et al. performed a retrospective 
cohort study by using inpatient electronic medical records to determine the incidence of C. 
difficile associated diarrhea in hospitalized IBD patients and found the incidence in IBD is higher 
than in the non-IBD patients191.  IBD and UC patients in particular had a higher risk for C. 
difficile associated diarrhea.  These data combined with our laboratory finding strong evidence of 
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alcohol’s role in IBD pathogenicity192, we sought to answer the question of whether consumption 
of alcohol not only impacts UC patient’s increased susceptibility to infection but also increases 
severity of symptoms related to bacterial infection.  
Hence, we adapted our model of UC and binge alcohol to include a low inoculate of C. 
rodentium in order to understand whether UC patients that drink alcohol would also have 
increased susceptibility to infection. Our results showed mice receiving C. rodentium following 
alcohol and DSS-induced colitis had decreased survival and increased weight loss, colon 
shortening, histopathology and clinical scores, and inflammation. Reappearance of UC 
symptoms during a flare stem from increases in intestinal inflammatory cytokines such as IFN-γ, 
IL-1, IL-6, and TNF-α6-11, which can directly lead to mucosal ulcerations, damage to the colonic 
epithelium, and crypt micro-abscesses193. Coupled with the knowledge that alcohol itself induces 
increases in inflammation it follows that alcohol consumption could either perpetuate a current 
UC flare, such as we’ve provided evidence for above, and/or trigger entrance into UC flare via 
initiation of the inflammatory cascade, which requires further investigation. This inflammation 
induced damage to the intestine and thus intestinal defense mechanisms could have dramatic 
consequences to UC patients, especially in combination with alcohol. Recent studies found that 
alcohol could cause a dysbiosis of the intestinal microbiome, which, in turn, could alter the 
intestinal microenvironment making it more favorable to opportunistic pathogens82. Therefore, it 
was imperative to understand the susceptibility to intestinal pathogens specifically after alcohol 
and DSS-induced colitis. With our low inoculate C. rodentium in combination with alcohol and 
DSS-induced colitis, we were able to show increases in susceptibility to infection in DSS 
Ethanol treated mice. We recognize the burden of utilizing the mouse pathogen, C. rodentium, 
which itself is used as a model of IBD, on top of our binge alcohol and DSS-induced colitis 
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model. Yet, our adaptation of using a much lower inoculate, 1 X 105 CFUs vs. 1 X 1011 CFUs to 
induce true IBD symptoms, allowed us to shed light on the increased propensity for UC patients 
that drink alcohol to acquire intestinal infections.  The idea that alcohol could act in such a way 
to worsen UC flare periods provides evidence to the clinician’s warning to UC patients to avoid 
drinking alcohol.  
A recent mouse study showed IL-22 mediated Reg3γ synthesis prevented colonization by 
antibiotic-resistant Enterococcus faecium via Toll-like receptor (TLR)-7 stimulation on dendritic 
cells194, and others have demonstrated that IL-22 mediated Clostridium difficile clearance from 
peripheral organs by upregulating systemic C3 complement activity195.  Future work in our 
laboratory will concentrate on combining our model of C. rodentium infection in UC and binge 
alcohol with our recombinant IL-22 or Lactobacillus delbrueckii treatment.  This will allow us to 
determine whether IL-22 or probiotic treatment Lactobacillus delbrueckii are sufficient in 
restoring intestinal barrier defense against invading pathogens in the context of UC and binge 
alcohol as assessed by increasing intestinal epithelial cell proliferation, AMPs, and anti-
inflammatory cytokines such as IL-10.   
Limitations 
We see several major limitations to our current studies. First is the inability to obtain 
patient tissue samples. While we would benefit greatly from studying the effects of alcohol and 
colitis in human intestine samples, our ability to receive proper control specimens would require 
physicians to take intestinal biopsies, or even perform non-invasive procedures such as 
colonoscopies on healthy individuals. The closest we are currently able to get to directly 
studying the effects of alcohol and IBD in human patient populations is through a retrospective 
analysis our laboratory conducted of patients admitted for IBD with a documented history of 
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alcohol use. Using the International Classification of Diseases, 9th Revision, Clinical 
Modification, (ICD-9-CM) diagnosis codes, we defined three study groups: IBD, UC, and CD.  
ICD-9-CM codes were also used to determine alcohol use.  Within this study, we found that 
alcohol negatively impacts clinical outcomes of patients with IBD, specifically increased 
intestinal infections, antibiotic injections, abdomen CT scans, and large intestine biopsies.  
Examination of intestinal infection diagnoses during the admission for either the IBD, UC, or CD 
study groups revealed that patients who were coded for alcohol use had significantly increased 
intestinal infections. The IBD + alcohol patients had increased Clostridium difficile intestinal 
infection, poorly defined intestinal infection, and overall intestinal infections. The UC + alcohol 
patients had increased poorly defined intestinal infections, while the CD + alcohol patients had 
increased intestinal infections of all types.  We would like to note that to be coded for an ICD-9 
diagnosis for an alcohol related disorder, the patient must have had some history of significant 
alcohol intake, thus our + alcohol study group likely comprises mostly heavy drinkers. 
Unfortunately, the databases do not contain information regarding the amount of alcohol a patient 
had prior to an admission. Furthermore, the databases do not contain the exact cause of the IBD 
admission, thus we could not discern whether a patient was admitted for a flare or other complication 
of IBD161. Therefore, the findings of this analysis warrant additional research of IBD patients that 
could provide more detailed information beyond what is available through ICD-9 codes.  
In addition to the lack of patient samples, a major limitation to the progress of our 
understanding how the microbiome may influence the intestinal epithelial barrier and/or 
intestinal immune cells. The role of the microbiome, and the ability to understand the 
contributions of individual species of bacteria to disease has largely been feasible due to 
experiments carried out in germ-free facilities. Another potential experiment to study the 
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interaction between microbiome and gut pathophysiology is to perform fecal transplant from 
mice following DSS-induced colitis and binge alcohol into naïve germ free mice to see if 
intestinal pathology would manifest in the absence of (i.e. just due to changes in the microbiome 
alone). Additionally, colonizing mice with a single species of bacteria, or a labeled species of 
bacteria would allow us to not only tease apart the influence of specific bacterial species 
following acute trauma, but also monitor the translocation of microbes from the gut and how that 
may directly influence other organs. We hope to establish collaborations in the future that may 
make performing these types of experiments possible in our model. 
We also would like to acknowledge that some of the experiments in this dissertation 
(specifically in chapter 6) have only been performed once. While we have carried out these 
experiments with an acceptable number of animals to run our statistical analyses, we are 
currently repeating these studies to verify our results before submitting these data to peer-
reviewed journals. 
Finally, we would like to address the use of male mice in our studies. We recognize that 
by only using male mice, we are missing how males and females may respond differently to 
colitis and binge alcohol. The largest reason for the absence of female mice from our studies is 
due to the need to align the estrous cycles of all the female animals involved in the study. High 
estrogen and progesterone levels during women’s menstrual cycles are known to increase 
severity of UC, and this is a mechanism that should be studied in future work.  New guidelines 
from the National Institutes of Health requiring both males and females to be used in 
experimental studies will allow for our laboratory to begin work on this mechanism.  
 
 
109 
 
 
Conclusions 
We have just begun to scratch the surface of studying alcohol in the context of UC.  
However, together, the current studies have bridged a significant gap in our current 
understanding of the effects of alcohol on UC pathophysiology in the intestines (Figure 28).  
Our work has shed light onto the physiologic, cellular, and molecular alterations to the intestinal 
barrier following DSS-induced colitis and alcohol.  Additionally, our work has provided a 
potential therapeutic outlet using IL-22 or the probiotic, Lactobacillus delbrueckii, which 
showed pre-clinical efficacy in our mouse model.  We have explored the role of the Jak/STAT 
signaling pathway using transgenic VillinCre STAT3 knockout mice to show the importance of 
this pathway in protection from alcohol induced exacerbated symptoms of UC.  Finally, we have 
contributed significant advances in determining that alcohol can increase susceptibility to 
infection with our C. rodentium model.  Future studies will certainly build on the foundation of 
this work and will further contribute to our understanding of how alcohol perpetuates UC flare.  
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Figure 38. Schematic of Major Findings Following Binge Alcohol and DSS-Induced Colitis 
With and Without rIL-22 or Lactobacillus delbrueckii Treatment. Treatment with IL-22 or 
Lactobacillus delbrueckii, leads to downstream activation of STAT3 (yellow), which results in 
intestinal barrier protection through potentially increasing AMP expression, reducing microbial 
dysbiosis, increasing mucus production, increasing anti-inflammatory cytokines, and promoting 
IEC proliferation to initiate entrance into UC remission (bottom panel). 
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